<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Metformin monotherapy for adults with type 2 diabetes mellitus - Gnesin, F - 2020 | Cochrane Library</title> <meta content="Metformin monotherapy for adults with type 2 diabetes mellitus - Gnesin, F - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012906.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Metformin monotherapy for adults with type 2 diabetes mellitus - Gnesin, F - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012906.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012906.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Metformin monotherapy for adults with type 2 diabetes mellitus" name="citation_title"/> <meta content="Filip Gnesin" name="citation_author"/> <meta content="Department 7652, Rigshospitalet" name="citation_author_institution"/> <meta content="filip.gnesin@gmail.com" name="citation_author_email"/> <meta content="Anne Cathrine Baun Thuesen" name="citation_author"/> <meta content="Lise Katrine Aronsen Kähler" name="citation_author"/> <meta content="University of Copenhagen" name="citation_author_institution"/> <meta content="Sten Madsbad" name="citation_author"/> <meta content="Hvidovre Hospital, University of Copenhagen" name="citation_author_institution"/> <meta content="Bianca Hemmingsen" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD012906.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/06/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012906.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012906.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012906.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Carbamates [adverse effects, therapeutic use]; Cardiovascular Diseases [mortality]; Cause of Death; Diabetes Mellitus, Type 2 [*drug therapy, mortality]; Dipeptidyl-Peptidase IV Inhibitors [adverse effects, therapeutic use]; Glucagon-Like Peptide 1 [analogs &amp; derivatives]; Hypoglycemic Agents [adverse effects, *therapeutic use]; Insulin [therapeutic use]; Metformin [adverse effects, *therapeutic use]; Myocardial Infarction [epidemiology]; Piperidines [adverse effects, therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Stroke [epidemiology]; Sulfonylurea Compounds [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012906.pub2&amp;doi=10.1002/14651858.CD012906.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012906\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012906\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","th","ms","id","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012906.pub2",title:"Metformin monotherapy for adults with type 2 diabetes mellitus",firstPublishedDate:"Jun 5, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012906.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012906.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012906.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012906.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012906.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012906.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012906.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012906.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012906.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012906.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>25470 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012906.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0203"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-sec-0197"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/appendices#CD012906-sec-0208"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/supinfo/CD012906-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/supinfo/CD012906-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Metformin monotherapy for adults with type 2 diabetes mellitus</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#CD012906-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Filip Gnesin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#CD012906-cr-0005">Anne Cathrine Baun Thuesen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#CD012906-cr-0006">Lise Katrine Aronsen Kähler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#CD012906-cr-0007">Sten Madsbad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information#CD012906-cr-0008">Bianca Hemmingsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information/en#CD012906-sec-0233">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 June 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012906.pub2">https://doi.org/10.1002/14651858.CD012906.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012906-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012906-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012906-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012906-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012906-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012906-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012906-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012906-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012906-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012906-abs-0001" lang="en"> <section id="CD012906-sec-0001"> <h3 class="title" id="CD012906-sec-0001">Background</h3> <p>Worldwide, there is an increasing incidence of type 2 diabetes mellitus (T2DM). Metformin is still the recommended first‐line glucose‐lowering drug for people with T2DM. Despite this, the effects of metformin on patient‐important outcomes are still not clarified. </p> </section> <section id="CD012906-sec-0002"> <h3 class="title" id="CD012906-sec-0002">Objectives</h3> <p>To assess the effects of metformin monotherapy in adults with T2DM.</p> </section> <section id="CD012906-sec-0003"> <h3 class="title" id="CD012906-sec-0003">Search methods</h3> <p>We based our search on a systematic report from the Agency for Healthcare Research and Quality, and topped‐up the search in CENTRAL, MEDLINE, Embase, WHO ICTRP, and ClinicalTrials.gov. Additionally, we searched the reference lists of included trials and systematic reviews, as well as health technology assessment reports and medical agencies. The date of the last search for all databases was 2 December 2019, except Embase (searched up 28 April 2017). </p> </section> <section id="CD012906-sec-0004"> <h3 class="title" id="CD012906-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) with at least one year's duration comparing metformin monotherapy with no intervention, behaviour changing interventions or other glucose‐lowering drugs in adults with T2DM. </p> </section> <section id="CD012906-sec-0005"> <h3 class="title" id="CD012906-sec-0005">Data collection and analysis</h3> <p>Two review authors read all abstracts and full‐text articles/records, assessed risk of bias, and extracted outcome data independently. We resolved discrepancies by involvement of a third review author. For meta‐analyses we used a random‐effects model with investigation of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the overall certainty of the evidence by using the GRADE instrument. </p> </section> <section id="CD012906-sec-0006"> <h3 class="title" id="CD012906-sec-0006">Main results</h3> <p>We included 18 RCTs with multiple study arms (N = 10,680). The percentage of participants finishing the trials was approximately 58% in all groups. Treatment duration ranged from one to 10.7 years. We judged no trials to be at low risk of bias on all 'Risk of bias' domains. The main outcomes of interest were all‐cause mortality, serious adverse events (SAEs), health‐related quality of life (HRQoL), cardiovascular mortality (CVM), non‐fatal myocardial infarction (NFMI), non‐fatal stroke (NFS), and end‐stage renal disease (ESRD). </p> <p>Two trials compared metformin (N = 370) with insulin (N = 454). Neither trial reported on all‐cause mortality, SAE, CVM, NFMI, NFS or ESRD. One trial provided information on HRQoL but did not show a substantial difference between the interventions. </p> <p>Seven trials compared metformin with sulphonylureas. Four trials reported on all‐cause mortality: in three trials no participant died, and in the remaining trial 31/1454 participants (2.1%) in the metformin group died compared with 31/1441 participants (2.2%) in the sulphonylurea group (very low‐certainty evidence). Three trials reported on SAE: in two trials no SAE occurred (186 participants); in the other trial 331/1454 participants (22.8%) in the metformin group experienced a SAE compared with 308/1441 participants (21.4%) in the sulphonylurea group (very low‐certainty evidence). Two trials reported on CVM: in one trial no CVM was observed and in the other trial 4/1441 participants (0.3%) in the metformin group died of cardiovascular reasons compared with 8/1447 participants (0.6%) in the sulphonylurea group (very low‐certainty evidence). Three trials reported on NFMI: in two trials no NFMI occurred, and in the other trial 21/1454 participants (1.4%) in the metformin group experienced a NFMI compared with 15/1441 participants (1.0%) in the sulphonylurea group (very low‐certainty evidence). One trial reported no NFS occurred (very low‐certainty evidence). No trial reported on HRQoL or ESRD. </p> <p>Seven trials compared metformin with thiazolidinediones (very low‐certainty evidence for all outcomes). Five trials reported on all‐cause mortality: in two trials no participant died; the overall RR was 0.88, 95% CI 0.55 to 1.39; P = 0.57; 5 trials; 4402 participants). Four trials reported on SAE, the RR was 0,95, 95% CI 0.84 to 1.09; P = 0.49; 3208 participants. Four trials reported on CVM, the RR was 0.71, 95% CI 0.21 to 2.39; P = 0.58; 3211 participants. Three trial reported on NFMI: in two trials no NFMI occurred and in one trial 21/1454 participants (1.4%) in the metformin group experienced a NFMI compared with 25/1456 participants (1.7%) in the thiazolidinedione group. One trial reported no NFS occurred. No trial reported on HRQoL or ESRD. </p> <p>Three trials compared metformin with dipeptidyl peptidase‐4 inhibitors (one trial each with saxagliptin, sitagliptin, vildagliptin with altogether 1977 participants). There was no substantial difference between the interventions for all‐cause mortality, SAE, CVM, NFMI and NFS (very low‐certainty evidence for all outcomes). </p> <p>One trial compared metformin with a glucagon‐like peptide‐1 analogue (very low‐certainty evidence for all reported outcomes). There was no substantial difference between the interventions for all‐cause mortality, CVM, NFMI and NFS. One or more SAEs were reported in 16/268 (6.0%) of the participants allocated to metformin compared with 35/539 (6.5%) of the participants allocated to a glucagon‐like peptide‐1 analogue. HRQoL or ESRD were not reported. </p> <p>One trial compared metformin with meglitinide and two trials compared metformin with no intervention. No deaths or SAEs occurred (very low‐certainty evidence)<br/>no other patient‐important outcomes were reported. </p> <p>No trial compared metformin with placebo or a behaviour changing interventions.</p> <p>Four ongoing trials with 5824 participants are likely to report one or more of our outcomes of interest and are estimated to be completed between 2018 and 2024. Furthermore, 24 trials with 2369 participants are awaiting assessment. </p> </section> <section id="CD012906-sec-0007"> <h3 class="title" id="CD012906-sec-0007">Authors' conclusions</h3> <p>There is no clear evidence whether metformin monotherapy compared with no intervention, behaviour changing interventions or other glucose‐lowering drugs influences patient‐important outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012906-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012906-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012906-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012906-abs-0021">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012906-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012906-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD012906-abs-0014">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012906-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012906-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012906-abs-0019">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012906-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012906-abs-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012906-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012906-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012906-abs-0002" lang="en"> <h3>Is metformin an effective treatment for adults with type 2 diabetes?</h3> <p><b>Background</b><br/>Type 2 diabetes is a condition that causes high levels of sugar in the blood. Blood sugar levels are controlled by insulin, a hormone made by the pancreas. Insulin instructs the liver, muscles and fat cells to remove sugar from the blood and store it. When the pancreas does not make enough insulin, or the body does not respond to insulin, too much sugar stays in the blood. Many medicines for treating type 2 diabetes are available. These aim to lower the amount of sugar in the blood and reduce long‐term complications of diabetes. The first medicine that is usually prescribed to people with type 2 diabetes is metformin. Metformin works by reducing the amount of sugar that the liver releases into the blood. It also improves the way the body responds to insulin. </p> <p>We wanted to find out whether metformin is an effective treatment for type 2 diabetes, and whether it causes any unwanted effects. We also wanted to compare its effects with other antidiabetic medicines, and with diets, exercise or both. The outcomes we were specifically interested in were death, serious unwanted events, health‐related quality of life, death from cardiovascular causes, and non‐fatal complications of diabetes (for example heart attacks, strokes or kidney failure). </p> <p><b>What did we look for?</b><br/>We searched medical databases for studies that:<br/>— were randomised controlled trials: randomised controlled trials are medical studies where participants are put randomly into one of the treatment groups. This type of study provides the most reliable evidence about whether treatments make a difference;<br/>— included people aged 18 years or older, with type 2 diabetes;<br/>— compared metformin with: a placebo (fake treatment); no treatment; diet programmes to help people eat well; or another medicine that lowers blood sugar levels;<br/>— lasted at least one year. </p> <p><b>What did we find?</b><br/>We found 18 studies with multiple study arms including a total of 10,680 participants. The studies lasted between one year and approximately 11 years. They compared metformin with:<br/>— insulin injections (two studies);<br/>— other medicines that lower blood sugar levels: sulphonylureas (seven studies); thiazolidinediones (seven studies); dipeptidyl peptidase‐4 inhibitors (three studies); a glucagon‐like peptide‐1 analogue (one study); a meglitinide (one study);<br/>— no treatment (two studies). </p> <p>No study compared metformin with a placebo or with diet or exercise programmes.</p> <p><b>Key results</b> <br/>Almost all studies investigated laboratory measurements of blood sugar control like fasting blood glucose. However, there was few information on patient‐important outcomes such as death, serious unwanted events, health‐related quality of life, death from cardiovascular causes, and non‐fatal complications of diabetes when comparing metformin with other medicines that lower blood sugar levels, placebo or no intervention. The available data did not show any clear benefit or harm of metformin. </p> <p>Four ongoing studies with 5824 participants will report one or more of our outcomes of interest andwill be completed between 2018 and 2024. Furthermore, 24 studies with 2369 participants could be used in a future update of our review once results are published. </p> <p><b>Certainty of the evidence</b> <br/>All the studies in this review were poorly conducted. The number of participants in most treatment comparisons was small. Even if studies reported some data we have very little confidence in the results of the comparisons. Future studies may substantially change our findings. </p> <p><b>How up to date is this review?</b><br/>This evidence is up to date as of 2 December 2019. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012906-sec-0203" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012906-sec-0203"></div> <h3 class="title" id="CD012906-sec-0204">Implications for practice</h3> <section id="CD012906-sec-0204"> <p>There is no clear evidence whether metformin monotherapy compared with no intervention, placebo, diet, or glucose‐lowering drugs has any benefit or harm for most patient‐important outcomes (all‐cause mortality, serious adverse events, health‐related quality of life, macrovascular and microvascular complications). There were fewer reported severe hypoglycaemic episodes with metformin compared to sulphonylureas. However, the results of our review are limited due to very low‐certainty evidence. No trial compared metformin monotherapy with placebo or diet, and no trial reported on blindness, end‐stage renal disease, amputation of lower extremity, lactic acidosis, or socioeconomic effects. We identified four ongoing trials and 24 trials awaiting assessment. In total, these trials will include approximately 8193 participants and could have an impact on our results. </p> </section> <h3 class="title" id="CD012906-sec-0205">Implications for research</h3> <section id="CD012906-sec-0205"> <p>It is currently unclear how metformin monotherapy compared with no intervention, placebo, diet or glucose‐lowering drugs affects patient‐important outcomes. Four ongoing trials with 5824 participants are likely to report one or more of our outcomes of interest and are estimated to be completed between 2018 and 2024. Furthermore, 24 trials with 2369 participants are awaiting assessment. The current evidence suffers from very low‐certainty evidence mainly due to risk of bias and serious imprecision. Thus, more large and well‐powered randomised controlled trials with low risk of bias, focusing on patient‐important outcomes are warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012906-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012906-sec-0008"></div> <div class="table" id="CD012906-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus insulin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with insulin for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> insulin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>(Short Form‐36 version 2 questionnaire)</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No substantial difference in mental or physical health‐related quality of life between the intervention groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0209">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012906-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus sulphonylureas</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with sulphonylureas for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> sulphonylureas (glibenclamide/glyburide, gliclazide, glipizide, glimepiride) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sulphonylureas<br/>(glibenclamide/glyburide, gliclazide, glipizide, glimepiride)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3129 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials: no participant died (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>) </p> <p>1 trial: 31/1454 participants (2.1%) in the metformin group died vs 31/1441 participants (2.2%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3081 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no SAE occurred (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>) </p> <p>1 trial: 331/1454 participants (22.8%) in the metformin group experienced a SAE compared with 308/1441 participants (21.4%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2940 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no CVM was observed (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>)<br/>1 trial: 4/1455 participants (0.3%) in the metformin group died of cardiovascular reasons vs 8/1447 participants (0.6%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3047 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no NFMI occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>)<br/>1 trial: 21/1454 participants (1.4%) in the metformin group experienced a NFMI vs 15/1441 participants (1.0%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no NFS occurred (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0210">Appendix 2</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012906-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus thiazolidinediones</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with thiazolidinediones for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> thiazolidinediones (pioglitazone, rosiglitazone) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Thiazolidinediones<br/>(pioglitazone, rosiglitazone)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> (9 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> (0.55 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4402 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no deaths occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) </p> <p>1 trial contributed 65/71 events (91.5%) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b> (184 to 239) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.84 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3208 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no SAE occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (0.21 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3211 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3020 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no NFMI occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>)<br/>1 trial: 21/1454 participants (1.4%) in the metformin group experienced a NFMI vs 25/1456 participants (1.7%) in the thiazolidinedione group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no NFS occurred (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0211">Appendix 3</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012906-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus dipeptidyl‐peptidase 4 inhibitors</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with dipeptidyl peptidase‐4 inhibitors for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> dipeptidyl peptidase‐4 inhibitors (saxagliptin, sitagliptin, vildagliptin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dipeptidyl peptidase‐4 inhibitors</b><br/>(saxagliptin, sitagliptin, vildagliptin) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 5/328 (1.5%) participants in the metformin group died vs 2/335 (0.6%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>)<br/>1 trial: 1/364 (0.3%) participants in the metformin group died vs 0/179 in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> <p>1 trial: 4/252 (1.6%) participants in the metformin group died vs 3/519 (0.6%) in the vildagliptin group (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 15/328 (4.5%) participants in the metformin group experienced a SAE vs 16/335 (4.8%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>)<br/>1 trial: 16/364 (4.4%) participants in the metformin group experienced a SAE vs 13/179 (7.2%) participants in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> <p>1 trial: 13/252 (5.2%) participants in the metformin group experienced a SAE vs 35/519 (6.7%) participants in the vildagliptin group (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>1 trial: 3/328 (0.9%) participants in the metformin group died due to cardiovascular disease vs 2/335 (0.6%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 1/364 (0.3%) participants in the metformin group experienced a NFMI vs 0/179 participants in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no NFS occurred (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0212">Appendix 4</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012906-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus glucagon like peptide‐1 analogues</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with glucagon like peptide‐1 analogues for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> glucagon like peptide‐1 analogues (dulaglutide) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Glucagon like peptide‐1 analogues<br/>(dulaglutide)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" class="headercell" colspan="6" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no deaths occurred (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 16/268 (6.0%) participants in the metformin group experienced a SAE vs 35/539 (6.5%) participants in the dulaglutide group (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 0/268 participants in the metformin group experienced a NFMI vs 1/539 (0.2%) participants in the dulaglutide group (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 0/268 participants in the metformin group experienced a NFS vs 1/539 (0.2%) participants in the dulaglutide group (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0213">Appendix 5</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012906-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus meglitinides</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with another glucose‐lowering drug for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> meglitinide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metiglinide<br/>(repaglinide)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no SAE occurred (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0214">Appendix 6</a> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012906-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012906-sec-0009"></div> <section id="CD012906-sec-0010"> <h3 class="title" id="CD012906-sec-0010">Description of the condition</h3> <p>According to the International Diabetes Federation (IDF), 382 million people worldwide had diabetes in 2013, and this number is estimated to be 592 million by 2035 (<a href="./references#CD012906-bbs2-0176" title="GuariguataL , WhitingDR , HambletonI , BeagleyJ , LinnenkampU , ShawJE . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice2014;103(2):137-49. [PMID: 24630390]">Guariguata 2014</a>). Type 2 diabetes mellitus (T2DM) is a condition characterised by insulin resistance and a relative deficiency of insulin secretion (<a href="./references#CD012906-bbs2-0214" title="TriplittC , Solis-HerreraC , ReasnerC , DeFronzoRA , CersosimoE . Classification of diabetes mellitus (Updated 2015 Mar 9). In: De GrootLJ , Beck-PeccozP , ChrousosG , et al, editors(s). Endotext (Internet). Available from: www.ncbi.nlm.nih.gov/books/NBK279119/ edition. South Dartmouth (MA): MDText.com, Inc., 2000. [PMID: 25905343]">Triplitt 2015</a>). Long‐term complications of T2DM are microvascular (e.g. nephropathy, retinopathy, neuropathy), as well as macrovascular (e.g. ischaemic heart disease, stroke, and ischaemia of the lower extremities). Mortality is increased among individuals with T2DM compared to people without T2DM. The main cause of the increased mortality is macrovascular disease (<a href="./references#CD012906-bbs2-0159" title="AlmdalT , ScharlingH , JensenJS , VestergaardH . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Archives of Internal Medicine2004;164(13):1422-6. [PMID: 15249351]">Almdal 2004</a>; <a href="./references#CD012906-bbs2-0170" title="deMarcoR , LocatelliF , ZoppiniG , VerlatoG , BonoraE , MuggeoM . Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care1999;22(5):756-61. [PMID: 10332677]">de Marco 1999</a>; <a href="./references#CD012906-bbs2-0212" title="StamlerJ , VaccaroO , NeatonJD , WentworthD . Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16(2):434-44. [PMID: 8432214]">Stamler 1993</a>). </p> </section> <section id="CD012906-sec-0011"> <h3 class="title" id="CD012906-sec-0011">Description of the intervention</h3> <p>People with T2DM are initially advised to follow behaviour changing ('lifestyle') interventions including weight loss and increased physical activity (<a href="./references#CD012906-bbs2-0157" title="InzucchiSE , BergenstalRM , BuseJB , DiamantM , FerranniniE , NauckM , et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2015;58(3):429-42. [PMID: 25583541]">ADA/EASD 2015</a>). However, over time the majority of people with T2DM will require additional glucose‐lowering pharmacological interventions. Currently, metformin is the recommended first‐line glucose‐lowering drug (<a href="./references#CD012906-bbs2-0156" title="NathanDM , BuseJB , DavidsonMB , FerranniniE , HolmanRR , SherwinR , et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2009;52(1):17-30. [PMID: 18941734]">ADA/EASD 2009</a>). The pivotal trial underlying the recommendation of metformin as the first‐line glucose‐lowering drug was the UK Prospective Diabetes Study (UKPDS), which compared metformin as monotherapy with chlorpropamide, glyburide and insulin in a subgroup of overweight participants (N = 342 out of a total number of included participants of 4075) (<a href="./references#CD012906-bbs2-0215" title="UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352(9131):854-65. [PMID: 9742977]">UKPDS 1998</a>). Intensive glycaemic control with metformin decreased the risk of diabetes‐related outcomes compared with other glucose‐lowering agents analysed in one combined group. Metformin is a biguanide originating from the plant <i>Galega officinalis</i> (<a href="./references#CD012906-bbs2-0218" title="WittersLA . The blooming of the French lilac. Journal of Clinical Investigation2001;108(8):1105-7.">Witters 2001</a>). Metformin was first described in 1922, and was administered to humans for the first time in France in 1957. In 1972, Canada approved its use for T2DM and later, in 1994, it received approval for use in T2DM by the US Food and Drug Administration (FDA) (<a href="./references#CD012906-bbs2-0169" title="CoreyEJ , CzakóB , KürtiL . Molecules and Medicine. Hoboken, NJ: Wiley, 2007. [978-0-470-22749-7]">Corey 2007</a>). </p> <section id="CD012906-sec-0012"> <h4 class="title">Adverse effects of metformin</h4> <p>The most common adverse effects of metformin are gastrointestinal disturbances, which are reported in 20% to 30% of people on metformin. However, the gastrointestinal disturbances only rarely necessitate discontinuation of metformin (<a href="./references#CD012906-bbs2-0172" title="DeFronzoRA . Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine1999;131(4):281-303.">DeFronzo 1999</a>). </p> <p>A potential complication of metformin use is lactic acidosis, a rare, but potentially fatal, metabolic condition that can occur whenever substantial tissue hypoxia exists (<a href="./references#CD012906-bbs2-0194" title="KreisbergRA . Lactate homeostasis and lactic acidosis. Annals of Internal Medicine1980;92(2 Pt 1):227-37. [PMID: 6766289]">Kreisberg 1980</a>). Lactic acidosis is characterised by elevated blood lactate concentrations (exceeding 5.0 mmol/L) and decreased blood pH (less than 7.35). The mortality is estimated to be about 50% (<a href="./references#CD012906-bbs2-0189" title="HuangW , CastelinoRL , PetersonGM . Lactic acidosis and the relationship with metformin usage: Case reports. Medicine2016;95(46):e4998. [PMID: 27861334]">Huang 2016</a>). A Cochrane Review did not show that metformin was associated with an increased risk of lactic acidosis or elevated lactate levels when compared to other glucose‐lowering drugs (<a href="./references#CD012906-bbs2-0205" title="SalpeterSR , GreyberE , PasternakGA , SalpeterEE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD002967. [DOI: 10.1002/14651858.CD002967.pub4]">Salpeter 2010</a>). However, several case reports of lactic acidosis in people receiving metformin have been published subsequently (<a href="./references#CD012906-bbs2-0192" title="Kalantar-ZadehK , UppotRN , LewandrowskiKB . Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion. New England Journal of Medicine2013;369(4):374-82. [PMID: 23841704]">Kalantar‐Zadeh 2013</a>; <a href="./references#CD012906-bbs2-0208" title="SchousboeK , El FassiD , SecherEL , ElmingH , RasmussenK , HornumM . Treatment of metformin-associated lactate acidosis by haemodialysis [Behandling af metforminassocieret laktatacidose med haemodialyse]. Ugeskrift for Laeger2012;174(23):1604-6. [PMID: 22673381]">Schousboe 2012</a>). </p> </section> </section> <section id="CD012906-sec-0013"> <h3 class="title" id="CD012906-sec-0013">How the intervention might work</h3> <p>The exact mechanism(s) of action of metformin are not clearly elucidated. However, metformin is known to alter carbohydrate metabolism by stimulating glucagon‐like peptide (GLP‐1) secretion which inhibits glucagon secretion leading to suppressed basal hepatic glucose production (gluconeogenesis) (<a href="./references#CD012906-bbs2-0201" title="RenaG , HardieDG , PearsonER . The mechanisms of action of metformin. Diabetologia2017;60(9):1577-85.">Rena 2017</a>). Other mechanisms include improving insulin sensitivity in the liver and peripheral tissues, as well as increasing insulin‐stimulated glucose uptake and utilisation in peripheral tissues (<a href="./references#CD012906-bbs2-0158" title="American Hospital Formulary Service (AHFS). Metformin hydrochloride. American Hospital Formulary Service Drug Information. Bethesda, USA: American Society of Health-System Pharmacists, Inc.1999;2755–63.">AHFS 1999</a>). It has been proposed that its prime mode of action is via activation of the 5' adenosine monophosphate‐activated protein kinase (AMPK) enzyme (<a href="./references#CD012906-bbs2-0166" title="ChoK , ChungJY , ChoSK , ShinHW , JangIJ , ParkJW , et al. Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRalpha/POMC pathway. Scientific Reports2015;5(-):8145. [PMID: 25634597]">Cho 2015</a>; <a href="./references#CD012906-bbs2-0173" title="DucaFA , CoteCD , RasmussenBA , Zadeh-TahmasebiM , RutterGA , FilippiBM , et al. Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production in rats. Nature Medicine2015;21(5):506-11. [PMID: 25849133]">Duca 2015</a>). </p> </section> <section id="CD012906-sec-0014"> <h3 class="title" id="CD012906-sec-0014">Why it is important to do this review</h3> <p>A previously published systematic review on sulphonylurea monotherapy versus metformin monotherapy in people with T2DM did not show superiority of metformin monotherapy (<a href="./references#CD012906-bbs2-0179" title="HemmingsenB , SchrollJB , WetterslevJ , GluudC , VaagA , SonneDP , et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open2014;2(3):E162-75. [PMID: 25295236]">Hemmingsen 2014</a>). However, no updated review on metformin monotherapy compared with other glucose‐lowering interventions in people with T2DM exists. In 2005, a Cochrane Review about metformin monotherapy was published (<a href="./references#CD012906-bbs2-0204" title="SaenzA , Fernandez-EstebanI , MataixA , AusejoM , RoqueM , MoherD . Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002966. [DOI: 10.1002/14651858.CD002966.pub3]">Saenz 2005</a>). However, this systematic review is more than 10 years old and was consequently withdrawn. Therefore, a new systematic review with updated searches and newer methodology is warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012906-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012906-sec-0015"></div> <p>To assess the effects of metformin monotherapy in adults with type 2 diabetes mellitus.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012906-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012906-sec-0016"></div> <section id="CD012906-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012906-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD012906-sec-0019"> <h4 class="title">Types of participants</h4> <p>Adults (18 years or more) with type 2 diabetes mellitus (T2DM).</p> <section id="CD012906-sec-0020"> <h5 class="title">Diagnostic criteria for diabetes mellitus</h5> <p>In order to be consistent with changes in the classification of and diagnostic criteria for diabetes mellitus over the years, the diagnosis should be established using the standard criteria valid at the time of trial commencement (for example <a href="./references#CD012906-bbs2-0154" title="American Diabetes Association (ADA) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26(Suppl 1):S5-20.">ADA 2003</a>; <a href="./references#CD012906-bbs2-0155" title="American Diabetes Association (ADA). Standards of medical care in diabetes - 2008. Diabetes Care2008;31(Suppl 1):S12-54. [PMID: 18165335]">ADA 2008</a>; <a href="./references#CD012906-bbs2-0217" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15(7):539-53.">WHO 1998</a>). Ideally, the diagnostic criteria should have been described. We used the trial authors' definition of diabetes mellitus if necessary. We planned to subject diagnostic criteria to a sensitivity analysis. </p> </section> </section> <section id="CD012906-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of intervention versus control/comparator.</p> <section id="CD012906-sec-0022"> <h5 class="title">Intervention</h5> <p>Metformin monotherapy.</p> </section> <section id="CD012906-sec-0023"> <h5 class="title">Comparisons</h5> <p> <ul id="CD012906-list-0001"> <li> <p>Placebo.</p> </li> <li> <p>No intervention.</p> </li> <li> <p>Diet.</p> </li> <li> <p>Other glucose‐lowering drugs.</p> </li> </ul> </p> <p>Concomitant interventions and glycaemic target had to be the same in both the intervention and comparator groups to establish fair comparisons. </p> <p>If a trial included multiple arms, we included any arm that met the review inclusion criteria. We excluded studies comparing metformin monotherapy with first‐generation sulphonylurea, as this compound is rarely used. </p> </section> <section id="CD012906-sec-0024"> <h5 class="title">Minimum duration of intervention and follow‐up</h5> <p>We included trials with at least one year's duration, irrespective of the post‐intervention follow‐up. The reason was that we were primarily interested in patient‐important outcomes and not in short‐term biochemical responses. </p> </section> <section id="CD012906-sec-0025"> <h5 class="title">Summary of specific exclusion criteria</h5> <p>We excluded trials of the following category.</p> <p> <ul id="CD012906-list-0002"> <li> <p>Intervention period less than one year.</p> </li> <li> <p>Not type 2 diabetes mellitus.</p> </li> <li> <p>Other comorbidities.</p> </li> </ul> </p> <p>Hypertension and hyperlipidaemia are conditions often associated with type 2 diabetes mellitus, and studies including people with these conditions were not excluded. Studies including people with other medical conditions, e.g. liver failure, were excluded. </p> </section> </section> <section id="CD012906-sec-0026"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude a trial if it failed to report one or several of our primary or secondary outcome measures. In cases where none of our primary or secondary outcomes were reported, we included the trial and contacted the corresponding author for supplementary data. If no additional data were available, we planned to provide some basic information in a supplementary table. </p> <p>We investigated the following outcomes using the methods and time points specified below. </p> <section id="CD012906-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012906-list-0003"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Health‐related quality of life.</p> </li> </ul> </p> </section> <section id="CD012906-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012906-list-0004"> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal myocardial infarction.</p> </li> <li> <p>Non‐fatal stroke.</p> </li> <li> <p>End‐stage renal disease.</p> </li> <li> <p>Blindness.</p> </li> <li> <p>Severe hypoglycaemia.</p> </li> </ul> </p> <section id="CD012906-sec-0029"> <h6 class="title">Explorative outcomes</h6> <p> <ul id="CD012906-list-0005"> <li> <p>Anthropometric measures.</p> </li> <li> <p>Glycaemic control.</p> </li> <li> <p>Lactic acidosis.</p> </li> <li> <p>Amputation of lower extremity.</p> </li> <li> <p>Congestive heart failure.</p> </li> <li> <p>Cardiac revascularisation.</p> </li> <li> <p>Peripheral revascularisation.</p> </li> <li> <p>Socioeconomic effects.</p> </li> <li> <p>Intervention failure.</p> </li> </ul> </p> </section> <section id="CD012906-sec-0030"> <h6 class="title">Method of outcome measurement</h6> <p> <ul id="CD012906-list-0006"> <li> <p>All‐cause mortality: defined as death from any cause.</p> </li> <li> <p>Serious adverse events: defined according to the International Conference on Harmonization Guidelines as, "any event that leads to death, that is life‐threatening, required in‐patient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability, and any important medical event which may have had jeopardised the patient or required intervention to prevent it" (<a href="./references#CD012906-bbs2-0190" title="EU, MHLW, FDA. In: International Conference on Harmonization Guideline for Good Clinical Practice. 1997.">ICH 1997</a>), or as reported in trials. </p> </li> <li> <p>Health‐related quality of life: defined as mental and physical quality of life and evaluated by a validated instrument such as Short‐Form 36. </p> </li> <li> <p>Cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, blindness: defined as reported in trials. </p> </li> <li> <p>End‐stage renal disease: defined as dialysis, renal transplantation: defined as reported in trials. </p> </li> <li> <p>Severe hypoglycaemia: requiring assistance from another person.</p> </li> <li> <p>Anthropometric measures: defined as weight in kg or body mass index (BMI).</p> </li> <li> <p>Glycaemic control: defined as glycosylated haemoglobin A1c (HbA1c) or fasting plasma glucose (FPG). </p> </li> <li> <p>Lactic acidosis: defined as reported in trials.</p> </li> <li> <p>Amputation of lower extremity: defined as reported in trials.</p> </li> <li> <p>Congestive heart failure: defined as reported in trials.</p> </li> <li> <p>Cardiac revascularisation: defined as reported in trials.</p> </li> <li> <p>Peripheral revascularisation: defined as reported in trials.</p> </li> <li> <p>Socioeconomic effects: such as direct costs defined as admission/readmission rates, average length of stay, visits to general practitioner, accident/emergency visits; medication consumption; indirect costs defined as resources lost due to illness by the participant or their family member. </p> </li> <li> <p>Intervention failure: defined as requiring additional treatment.</p> </li> </ul> </p> </section> <section id="CD012906-sec-0031"> <h6 class="title">Timing of outcome measurement</h6> <p> <ul id="CD012906-list-0007"> <li> <p>At the end of the intervention period: health‐related quality of life, anthropometric measures, glycaemic control. </p> </li> <li> <p>Any time after participants were randomised to intervention/comparator groups: all other outcomes. </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012906-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012906-sec-0033"> <h4 class="title">Electronic searches</h4> <p>In 2016, the Agency for Healthcare Research and Quality (AHRQ) published a systematic review and meta‐analysis (<a href="./references#CD012906-bbs2-0197" title="MaruthurNM , TsengE , HutflessS , WilsonLM , Suarez-CuervoC , BergerZ , et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Annals of Internal Medicine2016;164(11):740-51. [DOI: 10.7326/M15-2650]">Maruthur 2016</a>), based on an extensive AHRQ report (<a href="./references#CD012906-bbs2-0162" title="BolenS , TsengE , HutflessS , SegalJB , Suarez-CuervoC , BergerZ , et al. Diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Review No. 173. Rockville (MD): Agency for Healthcare Research and Quality; 2016 Apr. AHRQ Publication No. 16-EHC013-EF2016.">Bolen 2016</a>), in which the authors evaluated the comparative effectiveness and safety of glucose‐lowering interventions for people with T2DM, including metformin monotherapy. This report included a systematic search of several databases up to April 2015 and a further update of the MEDLINE search up to December 2015. </p> <p>Because the scientific publication output with regard to this review´ topic is immense (metformin is a widely used medication which has been available for several decades), we based the identification of eligible studies on the results of the AHRQ report and topped‐up their search with our own search strategy from 2014 onwards. We placed no restrictions on the language of publication.<br/>We searched the following literature databases. </p> <p> <ul id="CD012906-list-0008"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) (searched up to 2 December 2019). </p> </li> <li> <p>Ovid MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &lt;1946 to Present&gt; (searched up to 2 December 2019). </p> </li> <li> <p>Embase Ovid &lt;1974 to 2017 April 27&gt; (searched up to 28 April 2017).</p> </li> </ul> </p> <p>Additionally, we searched the following trials registers from inception onwards.</p> <p> <ul id="CD012906-list-0009"> <li> <p><a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (searched up to 2 December 2019). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch/</a>) (searched up to 2 December 2019). </p> </li> </ul> </p> <p>Details of all search strategies are presented in <a href="./appendices#CD012906-sec-0215">Appendix 7</a>. </p> </section> <section id="CD012906-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials, systematic reviews of metformin monotherapy and health technology assessment reports. In addition, we contacted authors of included trials to identify any additional information on the retrieved trials and to determine if further trials existed, which we might have missed. </p> <p>We also searched databases from regulatory agencies (European Medicines Agency (EMA), US Food and Drugs Administration (FDA)) (<a href="./references#CD012906-bbs2-0178" title="HartB , LundhA , BeroL . Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ2012;344:d7202. [DOI: 10.1136/bmj.d7202]">Hart 2012</a>; <a href="./references#CD012906-bbs2-0209" title="SchrollJB , BeroL . Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]. Cochrane Database of Systematic Reviews2015;4. [DOI: 10.1002/14651858.ED000098]">Schroll 2015</a>). </p> <p>We did not use abstracts or conference proceedings for data extraction unless full data were available from trial authors because this information source does not fulfil the <a href="./references#CD012906-bbs2-0167" title="CONSORT. The CONSORT statement. www.consort-statement.org (accessed 19 May 2019).">CONSORT</a> requirements, which consist of "an evidence‐based, minimum set of recommendations for reporting randomized trials" (<a href="./references#CD012906-bbs2-0167" title="CONSORT. The CONSORT statement. www.consort-statement.org (accessed 19 May 2019).">CONSORT</a>; <a href="./references#CD012906-bbs2-0207" title="SchererRW , LangenbergP , vonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: MR000005. [DOI: 10.1002/14651858.MR000005.pub3]">Scherer 2007</a>). We listed key data from abstracts in an appendix. We presented information on abstracts or conference proceedings in the '<a href="./references#CD012906-sec-0242" title="">Characteristics of studies awaiting classification</a>' table. </p> </section> </section> <section id="CD012906-sec-0035"> <h3 class="title" id="CD012906-sec-0035">Data collection and analysis</h3> <section id="CD012906-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (FG and AT or LK) independently scanned the abstract, title, or both of every record we retrieved in the literature searches, to determine which trials we should assess further. We obtained the full text of all potentially relevant records. We resolved any disagreements through consensus or by recourse to a third review author (AT or LK). If we could not resolve a disagreement, we categorised the trial as a 'study awaiting classification' and contacted the trial authors for clarification. We presented an adapted PRISMA flow diagram to show the process of trial selection (<a href="./references#CD012906-bbs2-0195" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLOS Medicine2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). We listed all articles excluded after full‐text assessment in the '<a href="./references#CD012906-sec-0241" title="">Characteristics of excluded studies</a>' table, and provided the reasons for exclusion. </p> </section> <section id="CD012906-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled inclusion criteria, two review authors (FG and AT or LK) independently extracted key participant and intervention characteristics. We described interventions according to the 'template for intervention description and replication' (TIDieR) checklist (<a href="./references#CD012906-bbs2-0185" title="HoffmannTC , GlasziouPP , BoutronI , MilneR , PereraR , MoherD , et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ2014;348:g1687.">Hoffmann 2014</a>; <a href="./references#CD012906-bbs2-0186" title="HoffmannTC , OxmanAD , IoannidisJP , MoherD , LassersonTJ , ToveyDI , et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ2017;358:j2998.">Hoffmann 2017</a>). We reported data on efficacy outcomes and adverse events using standardised CMED data extraction sheets. We resolved any disagreements by discussion or, if required, by consultation with a third review author (AT or LK) (for details see <a href="./references#CD012906-sec-0240" title="">Characteristics of included studies</a>; <a href="#CD012906-tbl-0007">Table 1</a>; <a href="./appendices#CD012906-sec-0216">Appendix 8</a>; <a href="./appendices#CD012906-sec-0217">Appendix 9</a>; <a href="./appendices#CD012906-sec-0218">Appendix 10</a>; <a href="./appendices#CD012906-sec-0219">Appendix 11</a>; <a href="./appendices#CD012906-sec-0220">Appendix 12</a>; <a href="./appendices#CD012906-sec-0221">Appendix 13</a>; <a href="./appendices#CD012906-sec-0222">Appendix 14</a>; <a href="./appendices#CD012906-sec-0223">Appendix 15</a>; <a href="./appendices#CD012906-sec-0224">Appendix 16</a>; <a href="./appendices#CD012906-sec-0225">Appendix 17</a>; <a href="./appendices#CD012906-sec-0226">Appendix 18</a>; <a href="./appendices#CD012906-sec-0227">Appendix 19</a>; <a href="./appendices#CD012906-sec-0228">Appendix 20</a>; <a href="./appendices#CD012906-sec-0209">Appendix 1</a>; <a href="./appendices#CD012906-sec-0210">Appendix 2</a>; <a href="./appendices#CD012906-sec-0211">Appendix 3</a>; <a href="./appendices#CD012906-sec-0212">Appendix 4</a>; <a href="./appendices#CD012906-sec-0213">Appendix 5</a>; <a href="./appendices#CD012906-sec-0214">Appendix 6</a>;<a href="./appendices#CD012906-sec-0229">Appendix 21</a>). </p> <div class="table" id="CD012906-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID<br/>(trial design)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial<br/>(%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Sample size calculation was based on a 30% dropout rate and a SD of 4% for percentage change from baseline in femoral neck, ensuring that the 95% confidence interval will be the mean +‐ 0.9% for each treatment group" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>226</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>225</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>162</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>71.7</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: gliclazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>57</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>57</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Considering as clinically significant a difference of at least 10% compared with the baseline and an α error of.05, the actual sample size is adequate to obtain a power higher than 0.80 for all variables related to glucose metabolism (HbA1c, FPG, PPG, FPI, PPI, GIR, and TGR)." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>15 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>136</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>120</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>88.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"We originally calculated that we would need to enroll 3600 patients to provide the study with a power of 90% to detect a 30% reduction in the risk of treatment failure for rosiglitazone, as compared with metformin and glyburide, at a significance level of P=0.05 (two‐sided, adjusted for two comparisons), assuming an event rate of 0.072 per year for metformin or glyburide and a rate of loss to follow‐up of 0.064 per year in each group. The protocol was amended in March 2002 to increase the number of patients to 4182 and in February 2004, to extend the follow‐up period beyond 4 years, in order to compensate for an overall rate of withdrawal that was greater than anticipated and an overall rate of primary outcome events that was lower than anticipated. The revised power estimate was 83%, assuming a rate of loss to follow‐up of 0.128 per year and a hazard rate for treatment failure of 0.035 per year." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Median of 4 years (maximum 6.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: rosiglitazone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.8</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4360</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4351</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2627</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A planned sample size of 660 patients (in 2 : 1 allocation ratio to vildagliptin: metformin) was calculated assuming a 20% drop‐out rate, with 90% power and a one‐sided significance level of 0.025 to detect non‐inferiority of vildagliptin compared with metformin in reducing HbA1c after 52 weeks, with a noninferiority margin of 0.3% and an expected difference between the two treatment groups of 0.0%. Based on health authority feedback, the test of non‐inferiority was amended during the course of the study to utilize a non‐inferiority margin of 0.4%, which increased the statistical power to 99%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254 (158)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 (158)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 (142)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.2 (55.9)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>526 (305)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511 (304)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378 (260)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.9 (49.4)<sup>b</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>780 (463)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>760 (462)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>569 (402)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>73.5 (52.7)<sup>b</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The study was designed with 90% power to detect noninferiority of dulaglutide 1.5 mg versus metformin on HbA1c change from baseline at the 26‐week primary end point with a margin of 0.4%, a SD of 1.3%, and a one‐sided a of 0.025, assuming no true difference between treatments. This corresponds to 251 patients per arm, with an assumed dropout rate of 11%. If noninferiority was met, superiority was assessed using a tree‐gatekeeping approach in which the type I error rate across all treatment comparisons for change from baseline in HbA1c at 26 weeks was strongly controlled at 0.025 (onesided). P values were adjusted so that each can be compared with 0.025 to assess significance while accounting for multiplicity adjustments. The analyses of efficacy and safety were based on the intent‐to‐treat population consisting of all randomized patients who received at least one dose of study treatment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: dulaglutide (1.5 mg/week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: dulaglutide (0.75 mg/week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.7</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>807</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>807</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>651</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>80.7</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"...each comparison was performed at the 0.027 alpha level from Dunnett’s adjustment so that the overall (family‐wise) type I error rate was controlled at the 0.05 significance level." </p> <p>"Based on the primary end‐point, the sample size afforded at least 90% power for both the combination comparisons and the individual components based on the min test by Laska and Meisner for normal case." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>76 weeks<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>663</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>663</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>428</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>64.6</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A noninferiority design was used in this study. Sample size was based on the study objective to disprove the null hypothesis that pioglitazone was inferior to metformin in terms of reduction in HbA1c. Based on a 5% significance level and a statistical power of 90%, a sample size of 450 patients in each treatment group was required." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>— (597<sup>e</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>— (597<sup>e</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1199</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1194</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1000</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>83.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"Our pretrial calculation showed that a two‐sided comparison of the pioglitazone vs. the diet‐alone group in Japanese patients required at least 30 patients per group to detect a difference in mean HbA1c of at least 1% with 5% significance and 95% power" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: glimepiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>114</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>106</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>106</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>93.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin (1000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 weeks<sup>f</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: metformin (2000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>543</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—<sup>g</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>240</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>44.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glimepiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>204</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>204</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glipizide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The power of the study was calculated with a Fisher's exact test, with a 0.050 two‐sided significance alpha level and a 90% power; to detect the difference between a glimepiride group proportion of 0.500 and a metformin group proportion of 0.750 the sample size in each group would be 85." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>60 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glimepiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>164</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>148</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>148</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"Table 6 gives the likelihood of detecting a 20 % or 25 % reduction of endpoints by improved plasma glucose and blood pressure control. This reduction has been accepted as being a clinically significant gain, particularly as benefits from treatment are likely to be even greater over a longer period of therapy since complications develop over many years. Power calculations assumed 8 % loss to follow‐up and a 4% per annum increased number of events as the cohort ages" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10.7 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1028</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1028</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a><sup>h</sup> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>54</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>54</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>54.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>14 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: repaglinide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>112</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.1</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Grand total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All interventions</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4041<sup>i</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2463<sup>j</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All c</b> omparator<b>s</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6639<sup>i</sup> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>3732<sup>j</sup> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All interventions and c</b> omparator<b>s</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10,680<sup>i</sup> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6195<sup>j</sup> </b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>—: denotes not reported<br/><sup>a</sup>After 52 weeks of metformin versus rosiglitazone all participants received open‐label metformin for an additional 24 weeks, which was not of interest to this review<br/><sup>b</sup>Participants also completing the 52‐week extension<br/><sup>c</sup>The trial consisted of a 52‐week intervention followed by a 52‐week extension period in which participants continued their allocated intervention<br/><sup>d</sup>The trial consisted of a 24‐week intervention followed by a 52‐week extension period in which participants continued their allocated intervention<br/><sup>e</sup>At least 597 participants were randomised to either arm. It is unclear which arm the remaining 5 participants were randomised to<br/><sup>f</sup>The trial consisted of a 24‐week intervention followed by a 30‐week extension period followed by an additional 52‐week extension period in which participants continued their allocated intervention<br/><sup>g</sup>Variation in number of participants analysed depending on outcome measure<br/><sup>h</sup>Results are after 2 years of intervention and follow‐up<br/><sup>i</sup>For <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a> numbers outside parentheses were used, for <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a> numbers in parentheses were used<br/><sup>j</sup>For <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>, <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a> and <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a> no numbers were available and thus not included in calculation </p> <p><b>C</b> : comparator; <b>I</b> : intervention; <b>GIR</b> : glucose infusion rate; <b>ITT</b> : intention‐to‐treat; <b>RCT</b> : randomised controlled trial; <b>SD</b> : standard deviation; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>FPG</b> : fasting plasma glucose; <b>FPI</b> : fasting plasma insulin; <b>PPG</b> : post prandial glucose; <b>PPI</b>: post prandial insulin. </p> </div> </div> <p>We provided information about potentially relevant ongoing trials, including the trial identifier in the '<a href="./references#CD012906-sec-0243" title="">Characteristics of ongoing studies</a>' table and in <a href="./appendices#CD012906-sec-0221">Appendix 13</a> 'Matrix of trial endpoints' (publications and trial documents). We tried to find the protocol of each included trial and reported primary, secondary and other outcomes measured by the study personnel (objectively) in comparison with the data from the publications in <a href="./appendices#CD012906-sec-0221">Appendix 13</a>. </p> <p>We emailed all authors of included trials to enquire whether they would be willing to answer questions regarding their trials. We presented the results of this survey in <a href="./appendices#CD012906-sec-0228">Appendix 20</a>. We then sought relevant missing information on the trial from the primary trial author(s), if required. </p> <section id="CD012906-sec-0038"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximised the information yield by collating all available data, and we used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial, and trial documents of included trials (such as trial registry information) as secondary references under the study ID of the included trial. Furthermore, we listed duplicate publications, companion documents, multiple reports of a trial, and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD012906-sec-0039"> <h5 class="title">Data from clinical trials registers</h5> <p>If data from included trials were available as study results in clinical trials registers, such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trials register, but no additional information (study results, publication or both) was available, we added this trial to the table '<a href="./references#CD012906-sec-0242" title="">Characteristics of studies awaiting classification</a>'. </p> </section> </section> <section id="CD012906-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (FG and LK or AT) independently assessed the risk of bias of each included trial. We resolved any disagreements by consensus, or by consultation with a fourth review author (BH). If risk of bias items were insufficiently described to evaluate risk of bias in publications, trial protocols or other sources, we contacted the trial authors for clarification. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD012906-bbs2-0184" title="HigginsJP , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>), assigning assessments of low, high, or unclear risk of bias (for details, see <a href="./appendices#CD012906-sec-0216">Appendix 8</a>; <a href="./appendices#CD012906-sec-0217">Appendix 9</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> according to the criteria and associated categorisations contained therein <i>(</i><a href="./references#CD012906-bbs2-0184" title="HigginsJP , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> <section id="CD012906-sec-0041"> <h5 class="title">Summary assessment of risk of bias</h5> <p>We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.</p> <p>We distinguished between self‐reported, investigator‐assessed and adjudicated outcome measures. </p> <p>We considered the following to be self‐reported outcomes.</p> <p> <ul id="CD012906-list-0010"> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Severe hypoglycaemia, as reported by participants.</p> </li> <li> <p>Anthropometric measures, as reported by participants.</p> </li> <li> <p>Glycaemic control, as reported by participants.</p> </li> </ul> </p> <p>We considered the following outcomes to be investigator‐assessed.</p> <p> <ul id="CD012906-list-0011"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal myocardial infarction.</p> </li> <li> <p>Non‐fatal stroke.</p> </li> <li> <p>End‐stage renal disease.</p> </li> <li> <p>Blindness.</p> </li> <li> <p>Amputation of lower extremity.</p> </li> <li> <p>Cardiac revascularisation.</p> </li> <li> <p>Peripheral revascularisation.</p> </li> <li> <p>Severe hypoglycaemia.</p> </li> <li> <p>Anthropometric measures.</p> </li> <li> <p>Glycaemic control.</p> </li> <li> <p>Lactic acidosis.</p> </li> <li> <p>Amputation of lower extremity.</p> </li> <li> <p>Congestive heart failure.</p> </li> <li> <p>Cardiac revascularisation.</p> </li> <li> <p>Peripheral revascularisation.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> <p><b>Risk of bias for a trial across outcomes</b> </p> <p>Some 'Risk of bias' domains, such as selection bias (sequence generation and allocation sequence concealment), affected the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, we marked all endpoints investigated in the associated trial as being at high risk. Otherwise, we would not perform a summary assessment of the risk of bias across all outcomes for a trial. </p> <p><b>Risk of bias for an outcome within a trial and across domains</b> </p> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains, unclear risk to denote an unclear risk of bias for one or more key domains and high risk to denote a high risk of bias for one or more key domains. </p> <p><b>Risk of bias for an outcome across trials and across domains</b> </p> <p>These were the main summary assessments that we incorporated into our judgments about the certainty of the evidence in the 'Summary of findings' tables. We defined outcomes as at low risk of bias when most information came from trials at low risk of bias, unclear risk when most information came from trials at low or unclear risk of bias and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> </section> </section> <section id="CD012906-sec-0042"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two trials were available for a comparison and a given outcome, we expressed dichotomous data as a risk ratio (RR) with 95% confidence interval (CI). We also intended to use odds ratio (OR) with 95% CI if appropriate.For continuous outcomes measured on the same scale (e.g. HbA1c), we estimated the intervention effect using the mean difference (MD) with 95% CI. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but using different measurement scales, we planned to calculate the standardised mean difference (SMD). The scales measuring health‐related quality of life could go in different directions. In some scales, values would increase with improved health‐related quality of life, whereas in other scales, values would decrease with improved health‐related quality of life. To adjust for the different directions of the scales, we planned to multiply scales that reported better health‐related quality of life using decreasing values by –1. We intended to re‐express the SMDs into the unit of the Short Form‐36 (SF‐36) questionnaire. This would have been done by using standard deviations from a clinical trial in participants with T2DM providing data for a pooled standard deviation for baseline and change from baseline. </p> <p>If included, we would have expressed time‐to‐event data as hazard ratio (HR) with 95% CI. We would have calculated HRs with the generic inverse variance method with 95% CI. </p> </section> <section id="CD012906-sec-0043"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over trials, cluster‐randomised trials, and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pair‐wise comparison or appropriately reduced the sample size so that the same participants did not contribute data to the meta‐analysis more than once (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (<a href="./references#CD012906-bbs2-0183" title="HigginsJP , DeeksJJ , Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p>We planned to re‐analyse cluster‐RCTs that had not appropriately adjusted for potential clustering of participants within clusters in their analyses. The variance of the intervention effects would be inflated by a design effect. Calculation of a design effect would involve estimation of an intracluster correlation coefficient (ICC). We planned to obtain estimates of ICCs through contact with authors or impute them by using either estimates from other included trials that reported ICCs or external estimates from empirical research (e.g. <a href="./references#CD012906-bbs2-0161" title="BellML , McKenzieJE . Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures. Psycho-oncology2013;22(8):1738-47.">Bell 2013</a>). We would have examined the impact of clustering using sensitivity analyses. </p> </section> <section id="CD012906-sec-0044"> <h4 class="title">Dealing with missing data</h4> <p>When possible, we requested missing data from the authors of the included trials. We carefully evaluated data such as screened, randomly assigned participants as well as intention‐to‐treat, and as‐treated and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward). </p> <p>In trials where the standard deviation (SD) of the outcome was not available at follow‐up or could not be recreated, we standardised by the average of the pooled baseline standard deviation from those trials in which this information was reported. </p> <p>In trials where means and SDs were not reported and the method mentioned above, and we did not receive the necessary information from trial authors, we imputed SDs by estimating the mean and variance from the median, range, and the size of the sample (<a href="./references#CD012906-bbs2-0187" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471-2288-5-13]">Hozo 2005</a>). </p> <p>We investigated the impact of imputation on meta‐analyses by performing sensitivity analyses, and we reported per outcome which trials were included with imputed SDs. </p> </section> <section id="CD012906-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as a pooled effect estimate. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD012906-bbs2-0171" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). In view of the low power of this test, we also considered the I² statistic (<a href="./references#CD012906-bbs2-0181" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>), which quantified inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012906-bbs2-0180" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21:1539-58.">Higgins 2002</a>)). </p> <p>When we found heterogeneity, we attempted to determine the possible reasons for it by examining individual trial and subgroup characteristics. </p> </section> <section id="CD012906-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>Had we included 10 or more trials investigating a particular outcome, we planned to use funnel plots to assess small‐trial effects. Several explanations could account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. Therefore, we planned to interpret the results carefully (<a href="./references#CD012906-bbs2-0213" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD012906-sec-0047"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if we judged participants, interventions, comparisons, and outcomes to be sufficiently similar to ensure an answer that was clinically meaningful. Unless good evidence showed homogeneous effects across trials of different methodological quality, we primarily summarised low risk of bias data using a random‐effects model (<a href="./references#CD012906-bbs2-0221" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration to the whole distribution of effects and presented a prediction interval (<a href="./references#CD012906-bbs2-0163" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta-analysis: I² is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5-18.">Borenstein 2017a</a>; <a href="./references#CD012906-bbs2-0164" title="BorensteinM . Prediction intervals. www.meta-analysis.com/prediction (accessed 3 July 2017).">Borenstein 2017b</a>; <a href="./references#CD012906-bbs2-0182" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172(1):137-59.">Higgins 2009</a>). A prediction interval needs at least three trials to be calculated and specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012906-bbs2-0203" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549.">Riley 2011</a>). For rare events such as event rates below 1%, we planned to use the Peto's odds ratio method, provided that there was no substantial imbalance between intervention and comparator group sizes and intervention effects were not exceptionally large. In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012906-bbs2-0171" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>; <a href="./references#CD012906-bbs2-0186" title="HoffmannTC , OxmanAD , IoannidisJP , MoherD , LassersonTJ , ToveyDI , et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ2017;358:j2998.">Hoffmann 2017</a>). </p> </section> <section id="CD012906-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out the following subgroup analyses with investigation of interactions (<a href="./references#CD012906-bbs2-0160" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PMID: 12543843]">Altman 2003</a>). </p> <p> <ul id="CD012906-list-0012"> <li> <p>Comparing trials of long duration (two years or longer) to trials of short duration (less than two years). </p> </li> <li> <p>Comparing trials including exclusively obese participants (defined as BMI ≥ 30) to trials including obese and non‐obese participants. </p> </li> <li> <p>Comparing trials at low risk of bias to trials at high risk of bias.</p> </li> </ul> </p> </section> <section id="CD012906-sec-0049"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD012906-list-0013"> <li> <p>Published trials.</p> </li> <li> <p>Very long or large trials to establish the extent to which they dominate the results.</p> </li> <li> <p>Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country. </p> </li> </ul> </p> <p>We also tested the robustness of results by repeating the analyses using different measures of effect size (RR, OR, etc) and different statistical models (fixed‐effect and random‐effects models). </p> <section id="CD012906-sec-0050"> <h5 class="title">Certainty of the evidence</h5> <p>We presented the overall certainty of the evidence for each outcome specified under 'Types of outcome measures: Summary of findings' according to the GRADE approach (<a href="./references#CD012906-bbs2-0177" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.)2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). The GRADE approach appraises the certainty of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Two review authors (BH and BR) independently rated the certainty of the evidence for each outcome. </p> <section id="CD012906-sec-0051"> <h6 class="title">'Summary of findings' table</h6> <p>We presented a summary of the evidence in a 'Summary of findings' table according to the GRADE approach (<a href="./references#CD012906-bbs2-0177" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.)2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). We included an appendix entitled 'Checklist to aid consistency and reproducibility of GRADE assessments', to help with standardisation of the 'Summary of findings' tables (<a href="./references#CD012906-bbs2-0199" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82.">Meader 2014</a>). Alternatively, we would have used the GRADEpro Guideline Development Tool (GDT) software and presented evidence profile tables as an appendix (<a href="./references#CD012906-bbs2-0175" title="GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.">GRADEproGDT 2015</a>). We presented results for the outcomes as described in the <a href="#CD012906-sec-0026">Types of outcome measures</a> section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of the evidence using footnotes and we made comments to aid the reader's understanding of the Cochrane Review where necessary. </p> <p>We created the 'Summary of findings' table using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012906-bbs2-0184" title="HigginsJP , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>; <a href="./references#CD012906-bbs2-0211" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.">Schünemann 2017</a>), along with Review Manager (RevMan 5.3) table editor (<a href="./references#CD012906-bbs2-0202" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>The intervention presented in the 'Summary of findings' table was metformin monotherapy and comparators were placebo, no intervention, behaviour changing interventions and other glucose‐lowering drugs or combinations of glucose‐lowering drugs. </p> <p>Our 'Summary of findings' tables and conclusions were based on the results of trials with a low risk of bias in all risk of bias domains (<a href="./references#CD012906-bbs2-0184" title="HigginsJP , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>; <a href="./references#CD012906-bbs2-0196" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] [PMID: 28207928]">Lundh 2017</a>; <a href="./references#CD012906-bbs2-0200" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13. [PMID: 9746022]">Moher 1998</a>; <a href="./references#CD012906-bbs2-0206" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38. [PMID: 22945832]">Savovic 2012</a>; <a href="./references#CD012906-bbs2-0210" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12. [PMID: 7823387]">Schulz 1995</a>; <a href="./references#CD012906-bbs2-0221" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). We reported the following outcomes, listed according to priority. </p> <p> <ul id="CD012906-list-0014"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal myocardial infarction.</p> </li> <li> <p>Non‐fatal stroke.</p> </li> <li> <p>End‐stage renal disease.</p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012906-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012906-sec-0052"></div> <section id="CD012906-sec-0053"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see the <a href="#CD012906-tbl-0007">Table 1</a>, '<a href="./references#CD012906-sec-0240" title="">Characteristics of included studies</a>', '<a href="./references#CD012906-sec-0241" title="">Characteristics of excluded studies</a>, and '<a href="./references#CD012906-sec-0243" title="">Characteristics of ongoing studies</a>' sections. </p> <section id="CD012906-sec-0054"> <h4 class="title">Results of the search</h4> <p>For an overview of trial selection, please see <a href="#CD012906-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012906-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram." data-id="CD012906-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> </div> <p>Our database searches identified 11,205 records. We excluded the majority of records on the basis of the title and abstract because they clearly did not meet inclusion criteria. We assessed a total of 186 full‐text articles/records for eligibility. Handsearching of reference lists of included trials and systematic reviews/meta‐analyses identified two additional publications/records (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0147" title="WangHB , DengXC , FengYT . Clinical observation of diabetes II treatment with acarbose and metformin. Modern Hospital2005;5(12):42–3. ">Wang 2005</a>). After screening, 46 trials published in 74 publications/records met our inclusion criteria. We included a total of 18 completed trials published in 46 publications/records in qualitative synthesis. Among them, we included 14 completed trials published in 38 publications/records in meta‐analyses. </p> <p>Twenty‐four of the 46 trials that met our inclusion criteria were published exclusively in English. The remaining 22 trials were published either exclusively or partly in other languages; one in Russian (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>), two in French (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>), 10 in Chinese (<a href="./references#CD012906-bbs2-0128" title="ChiCTR-IOR-16007720. Effects of oral hypoglycemic drugs on gut microbiota in patients with type 2 diabetes. www.chictr.org.cn/showprojen.aspx?proj=13034 (first registered 5 January 2016). ">ChiCTR‐IOR‐16007720</a>; <a href="./references#CD012906-bbs2-0129" title="ChiCTR-IOR-17011477. Effect of saxagliptin and Metformin on bone metabolism in patients with newly diagnosed type 2 diabetes. www.chictr.org.cn/showproj.aspx?proj=18373 (first registered 24 May 2017). ">ChiCTR‐IOR‐17011477</a>; <a href="./references#CD012906-bbs2-0130" title="ChiCTR-IPR-16009666. Effects of liraglutide on inducing long-term clinical remission in newly diagnosed type 2 diabetes after intensive treatment. www.chictr.org.cn/showprojen.aspx?proj=15885 (first registered 27 October 2016). ">ChiCTR‐IPR‐16009666</a>; <a href="./references#CD012906-bbs2-0131" title="ChiCTR-IPR-17010811. Determination for efficacy of aspirin with metformin in the treatment of type 2 diabetic patients with hyperglucagonemia. www.chictr.org.cn/hvshowproject.aspx?id=11165 (date of first registration not reported). ">ChiCTR‐IPR‐17010811</a>; <a href="./references#CD012906-bbs2-0132" title="ChiCTR-TCH-10001013. Pioglitazone and/or metformin as treatment for cognitive impairments and risk of stroke in patients with type 2 diabetes. www.chictr.org.cn/showproj.aspx?proj=8525 (first registered 9 September 2010). ">ChiCTR‐TCH‐10001013</a>; <a href="./references#CD012906-bbs2-0133" title="ChiCTR-TRC-11001331. Effects of DPP-4 inhibitor and /or metformin combination on type 2 diabetes. www.chictr.org.cn/hvshowproject.aspx?id=759 (date of first registration not reported). ">ChiCTR‐TRC‐11001331</a>; <a href="./references#CD012906-bbs2-0126" title="ChiCTR1800018825. Clinical efficacy and mechanism of Empagliflozin in the treatment of patients with new-onset type 2 diabetes and risk factor for atherosclerotic cardiovascular disease. http://www.chictr.org.cn/showproj.aspx?proj=30989 (first registered 11 October 2018). ">ChiCTR1800018825</a>; <a href="./references#CD012906-bbs2-0127" title="ChiCTR1900021632. Comparison of acarbose and metformin therapy on the efficacy of HbA1C, islet function and body weight in newly diagnosed elderly type 2 diabetic patients. http://www.chictr.org.cn/showproj.aspx?proj=35291 (first registered 2 March 2019). ">ChiCTR1900021632</a>; <a href="./references#CD012906-bbs2-0144" title="MaL , LiJ , ZhangL , YangR , ZhaoW , LiR . The effect of metformin and pioglitazone on glucagon of patients with diabetes and metabolic syndrome. [Chinese]. Chinese Journal of Clinical Nutrition2015;23(2):65-72. ">Ma 2015</a>; <a href="./references#CD012906-bbs2-0149" title="ZhangXY , DuJ , JiaY , BaiR , YangY , BaY , et al. Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus. National Medical Journal of China2009;89(30):2134-7. ">Zhang 2009</a>) and nine in Japanese (<a href="./references#CD012906-bbs2-0135" title="JPRN-UMIN000000689. Effect of pioglitazone on renal function amelioration by measurement of cystatine C levels in the type 2 diabetic patients. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000828 (first registered 31 March 2008). ">JPRN‐UMIN000000689</a>; <a href="./references#CD012906-bbs2-0136" title="JPRN-UMIN000000771. Multifactorial effects of insulin sensitizers. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000926 (first registered 16 July 2007). ">JPRN‐UMIN000000771</a>; <a href="./references#CD012906-bbs2-0137" title="JPRN-UMIN000001085. Effect of insulin sensitizer treatment on carotid arterial elasticity. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000874 (first registered 20 March 2008). ">JPRN‐UMIN000001085</a>; <a href="./references#CD012906-bbs2-0138" title="JPRN-UMIN000001891. Comparative efficacy of pioglitazone and metformin in glucose variability in type 2 diabetes. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002278 (first registered 15 April 2009). ">JPRN‐UMIN000001891</a>; <a href="./references#CD012906-bbs2-0139" title="JPRN-UMIN000002099. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002561 (first registered 21 June 2009). ">JPRN‐UMIN000002099</a>; <a href="./references#CD012906-bbs2-0140" title="JPRN-UMIN000003563. Intervention of type 2 DM with sitagliptin or high dose metformin trial in Kobe:INSIGHT-KOBE. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004321 (first registered 6 May 2010). ">JPRN‐UMIN000003563</a>; <a href="./references#CD012906-bbs2-0141" title="JPRN-UMIN000006504. Assessment of beneficial effects on left ventricular hypertrophy and diastolic function by metformin in hypertensive patients with type2 DM. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007716 (first registered 7 October 2011). ">JPRN‐UMIN000006504</a>; <a href="./references#CD012906-bbs2-0142" title="JPRN-UMIN000010624. Vildagliptin and biguanide on postprandial blood glucose and vascular endothelial function in type 2 diabetic patients with coronary artery disease. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012423 (first registered 1 May 2013). ">JPRN‐UMIN000010624</a>; <a href="./references#CD012906-bbs2-0143" title="JPRN-UMIN000014775. Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetes. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017180 (first registered 15 August 2014). ">JPRN‐UMIN000014775</a>). </p> <p>We excluded 107 studies described in 114 publications. The most frequent reason for exclusion was "intervention less than 1 year" which concerned 28 studies. We identified four potentially relevant ongoing trials (see '<a href="./references#CD012906-sec-0243" title="">Characteristics of ongoing studies</a>') and 24 trials awaiting assessment (see '<a href="./references#CD012906-sec-0242" title="">Characteristics of studies awaiting classification</a>'). Most of the studies classified as awaiting classification were clinical trials which were completed, but not yet published. </p> <p>Handsearching the reference list of a previous Cochrane Review on metformin monotherapy did not provide any additional trials (<a href="./references#CD012906-bbs2-0204" title="SaenzA , Fernandez-EstebanI , MataixA , AusejoM , RoqueM , MoherD . Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002966. [DOI: 10.1002/14651858.CD002966.pub3]">Saenz 2005</a>). </p> <p>We did not obtain additional references from contacting authors of included trials, screening references from the MEDLINE (Ovid SP) email alert service or searching databases from the European Medicines Agency. Searching the Food and Drug Aministration (FDA) provided additional information on one of the included trials (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0174" title="FDA. FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Assessed 20th September 2019.">FDA 1994</a>). It was not explicitly stated that the trial published by Campbell and colleagues and the trial in the FDA report was the same. In the FDA report a trial number was available. No trial number was available from the journal publication. However, we judged this to be the same trial as trial duration, country, intervention, number of participants, mean age and number of included men/women were identical between the two references (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0174" title="FDA. FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Assessed 20th September 2019.">FDA 1994</a>). Another study was identified from the FDA (trial number MET/D/86/BERGI) (<a href="./references#CD012906-bbs2-0174" title="FDA. FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Assessed 20th September 2019.">FDA 1994</a>). This study compared metformin with diet and had a two‐year duration. However, it was unclear from the FDA document whether this study was randomised and how many participants were included. We did not identify any published version of this study. Weight was the only reported outcome. Therefore, we excluded this study (<a href="./references#CD012906-bbs2-0174" title="FDA. FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Assessed 20th September 2019.">FDA 1994</a>). </p> </section> <section id="CD012906-sec-0055"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included trials is presented elsewhere (see '<a href="./references#CD012906-sec-0240" title="">Characteristics of included studies</a>' and <a href="./appendices#CD012906-sec-0219">Appendix 11</a>; <a href="./appendices#CD012906-sec-0220">Appendix 12</a>; <a href="./appendices#CD012906-sec-0221">Appendix 13</a>; <a href="./appendices#CD012906-sec-0222">Appendix 14</a>; <a href="./appendices#CD012906-sec-0223">Appendix 15</a>; <a href="./appendices#CD012906-sec-0224">Appendix 16</a>; <a href="./appendices#CD012906-sec-0225">Appendix 17</a>; <a href="./appendices#CD012906-sec-0226">Appendix 18</a>; <a href="./appendices#CD012906-sec-0227">Appendix 19</a>; <a href="./appendices#CD012906-sec-0228">Appendix 20</a>; <a href="./appendices#CD012906-sec-0229">Appendix 21</a>). The following is a succinct overview. </p> <section id="CD012906-sec-0056"> <h5 class="title">Source of data</h5> <p>All 18 included trials were published in medical journals. One trial had additional information in a FDA document (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). </p> <p>Seven trials provided a protocol in a trial register (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) or in a design paper (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). </p> <p>We contacted all authors of included trials and trials awaiting assessment by email if contact information was available (see '<a href="./appendices#CD012906-sec-0228">Appendix 20</a>'). Most of the references classified as awaiting classification were protocols for randomised clinical trials which were completed several years ago, but no publication could be retrieved. We received additional data for only one included trial (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). In addition, if important information was lacking on excluded trials, we contacted authors for clarification (see '<a href="./appendices#CD012906-sec-0228">Appendix 20</a>'). </p> </section> <section id="CD012906-sec-0057"> <h5 class="title">Comparisons</h5> <p>No trials compared metformin monotherapy with placebo or diet. Two trials compared metformin monotherapy with no intervention (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). Seven trials compared metformin monotherapy with sulphonylureas (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Two trials compared metformin monotherapy with insulin (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). Seven trials compared metformin monotherapy with thiazolidinediones (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Three trials compared metformin monotherapy with dipeptidyl peptidase 4‐inhibitors (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). One trial compared metformin monotherapy with a glucagon‐like peptide 1‐analogue (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). One trial compared metformin monotherapy with meglitinides (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>). </p> <p>Three trials had additional comparators that were not of interest to this review (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). One trial had two separate metformin monotherapy arms with different doses (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> </section> <section id="CD012906-sec-0058"> <h5 class="title">Overview of trial populations</h5> <p>For a detailed overview of trial populations, please see <a href="#CD012906-tbl-0007">Table 1</a>. </p> <p>Ten trials provided a description of sample size calculation (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Seven trials provided information on the number of screened/eligible participants (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>A total of 10,680 participants were randomised to metformin monotherapy (M) or comparator groups. A total of 4041 participants were randomised to metformin monotherapy, and 6639 participants were randomised to comparator groups. The percentage of participants finishing the trial was approximately 58% in all groups (dropout‐rate of 42%), approximately 61% in the metformin monotherapy groups and approximately 56% in the comparator groups. The total number of participants in the trials ranged from 48 participants (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>) to 4360 participants (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). The number of participants randomised to the metformin monotherapy group ranged from 24 to 1455 participants, and from 24 to 1458 participants in the comparator groups. </p> </section> <section id="CD012906-sec-0059"> <h5 class="title">Trial design</h5> <p>All 18 trials were randomised controlled trials (RCTs) with a parallel design.</p> <p>Two trials compared metformin monotherapy versus no intervention (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). The remaining 16 trials compared metformin monotherapy versus an active control. </p> <p>Seven trials were multicentre trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). Number of centres ranged from three to 488 centres. Five trials were single‐centre trials (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>). The remaining six trials did not report the number of centres. </p> <p>Seven trials did not report in which country they were conducted (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). Most of the remaining trials were conducted in Europe. </p> <p>Eight trials were double‐blinded for participants and personnel (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). Seven trials had an open‐label design (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). The remaining three trials did not report blinding status. </p> <p>Eight trials were blinded for outcome assessors (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). The remaining trials did not blind, or report blinding of outcome assessors. </p> <p>The trials were performed between 1977 and 2012.</p> <p>Duration of interventions ranged from one year to 10.7 years. Mean and median duration of intervention was approximately 100 weeks and 52 weeks, respectively. </p> <p>Duration of follow‐up ranged from one year to 10.7 years. Mean and median duration of follow‐up was approximately 100 weeks and 54 weeks, respectively. </p> <p>Twelve trials had a run‐in period prior to the intervention (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>No trials were terminated early.</p> </section> <section id="CD012906-sec-0060"> <h5 class="title">Settings</h5> <p>All trials were conducted in outpatient clinics.</p> </section> <section id="CD012906-sec-0061"> <h5 class="title">Participants</h5> <p>Most participants were White people.</p> <p>All trials included participants with T2DM. Four trials did not report the duration of T2DM (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>, <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>). In the remaining 14 trials, mean and median duration of T2DM was approximately 3.7 years and 3.3 years, respectively. </p> <p>Two trials included only female participants (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). In the remaining trials, the percentage of female participants ranged from 41% to 74%. </p> <p>Mean age of trial participants ranged from approximately 50.7 years to 64.0 years.</p> <p>Mean HbA1c at baseline ranged from 6.4% to 11.8%. Mean BMI at baseline ranged from 24.7 kg/m<sup>2</sup> to 34 kg/m<sup>2</sup>. </p> <p>Three trials did not report cointerventions/comedications used by participants (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>). In the remaining trials, the most frequent cointervention/comedication was diet and exercise. Four trials reported comorbidities of participants (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). The most frequent comorbidity was hypertension. </p> <p>Major exclusion criteria across all trials were type 1 diabetes mellitus, history of cardiovascular disease, renal dysfunction, liver dysfunction, pregnancy/lactating, known allergy towards trial drugs and known substance abuse. </p> </section> <section id="CD012906-sec-0062"> <h5 class="title">Diagnosis</h5> <p>Eleven trials did not report diagnostic criteria for T2DM. Across the remaining seven trials, several different diagnostic criteria were used: World Health Organization (WHO) 1999 (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>), American Diabetes Association (ADA) 2001 (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>), ADA 2006 (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>), ADA 2010 (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>), European Association for the Study of Diabetes (EASD) 2007 (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>) and trial author's definitions: fasting plasma glucose (FPG) greater than 8 mmol/L on two occasions two weeks apart on diet (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>) and FPG greater than 6 mmol/L on two occasions (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). </p> </section> <section id="CD012906-sec-0063"> <h5 class="title">Interventions</h5> <p>All trials randomised participants to a metformin monotherapy arm.</p> <p>Metformin monotherapy was administered orally as a single intervention arm in all but one of the trials (<a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>), where it was administered as two intervention arms in total daily doses of 1000 mg/day and 2000 mg/day, respectively. In the remaining trials, the total daily dose of metformin monotherapy ranged from 750 mg/day to 3000 mg/day, and the average total daily dose was approximately 2050 mg/day. </p> <p>Second‐generation sulphonylureas were administered orally as glibenclamide in two trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>), where the total daily dose ranged from 15 mg/day to 20 mg/day, and the average total daily dose was 17.5 mg/day; as gliclazide in one trial (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>), where the total daily dose was 120 mg/day; and as glipizide in one trial where the total daily dose was 30 mg/day (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). </p> <p>Third‐generation sulphonylureas were administered orally as the comparator arm as glimepiride in three trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>), where the total daily dose ranged from 1 mg/day to 8 mg/day, and the average total daily dose was approximately 5 mg/day. </p> <p>Insulin was administered subcutaneously in two trials (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). In one trial, insulin was administered as a long‐acting insulin in doses of 0.2 to 0.4 International Units (IU)/kg body weight/day in addition to a short‐acting insulin in doses of 1 IU/10 g carbohydrates to 1.5 IU/10 g carbohydrates (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). In one trial, insulin was primarily administered as a long‐acting insulin, and was supplemented by a short‐acting insulin if the daily dose exceeded 14 IU or the pre‐meal/bed‐time home blood glucose measurements were more than 7 mmol/L. </p> <p>Thiazolidinediones were administered orally as pioglitazone in four trials (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>), where the total daily dose was 45 mg/day in all trials; and as rosiglitazone in three trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>), where the total daily dose ranged from 4 mg/day to 8 mg/day, and the average daily dose was approximately 6.5 mg/day. </p> <p>Dipeptidyl dipeptidase 4‐inhibitors were administered orally as saxagliptin in one trial (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>), where the total daily dose was 10 mg/day; as sitagliptin in one trial (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>), where the total daily dose was 100 mg/day; and as vildagliptin in one trial (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>), where the total daily dose was 100 mg/day. </p> <p>Glucagon‐like peptide 1 receptor analogues were administered subcutaneously in one trial in total weekly doses of dulaglutide 0.75 mg/week and 1.5 mg/week, respectively (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). </p> <p>Meglitinides were administered orally as repaglinide in one trial (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>), where the total daily dose was 4 mg/day. </p> <p>'No intervention' was the comparator arm in two trials (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). </p> <p>We considered the intervention and comparator arms to be adequate in all but three of the trials, due to administering 'no intervention' (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>) or administering insufficient doses of metformin (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>), both of which did not establish fair comparisons. </p> <p>Rescue medication was administered as add‐on glibenclamide in two trials (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>); unspecified sulphonylurea in one trial (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>); insulin in one trial (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>); pioglitazone in two trials (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>); and an unspecified treatment in one trial (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). In one trial (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>), rescue medication was administered as add‐on glibenclamide in the metformin arm and could be switched to insulin if hyperglycaemia persisted; continued sulphonylurea or add‐on metformin in the comparator arm receiving sulphonylurea; and more complex insulin regimens in the comparator arm receiving basal insulin. In the remaining 11 trials, rescue medication was not administered. </p> <p>Three trials administered only diet as a cointervention (<a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). Six trials did not administer diet nor exercise as a cointervention (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). The remaining nine trials administered diet and exercise as cointerventions. </p> <p>Special cointerventions were administered in one trial (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>) orally as calcium and vitamin D in daily doses of 500 mg/day to 1000 mg/day and 400 IU/day, respectively. </p> </section> <section id="CD012906-sec-0064"> <h5 class="title">Outcomes</h5> <p>Eight trials explicitly stated a primary outcome in the publication. Of these trials, five trials were registered in ClinicalTrials.gov (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>), and the remaining three did not have any available trial documents (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Nine trials did not state a primary outcome in the publication. Of these trials, one was registered in ClinicalTrials.gov (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>), and the remaining eight did not have any available documents describing the trial protocol (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). One trial had a design article in which it was stated that metformin monotherapy would be compared separately with each sulphonylurea group for outcomes of interest for this review, however, these data were never reported (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). </p> <p>The most common primary outcome of the included trials was HbA1c.</p> <p>The total number of explicitly stated outcomes collected in the trials ranged from three (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>) to 20 (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>). The median number of explicitly stated outcomes in the trials was 11. </p> <p>All but seven of the trials reported all‐cause mortality (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). All but seven of the trials reported serious adverse events (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). All but eight of the trials reported adverse events (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). Only one trial reported on health‐related quality of life (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). This trial applied the Short‐form health survey 36 (<a href="./appendices#CD012906-sec-0229">Appendix 21</a>). </p> <p>Seven trials reported cardiovascular mortality (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). Five trials reported non‐fatal myocardial infarction (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Three trials reported non‐fatal stroke (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). No trials reported blindness or end‐stage renal disease. </p> <p>Eight trials reported body weight (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). Seven trials reported BMI (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). All but three of the trials reported FPG (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). All but three of the trials reported HbA1c (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). Four trials reported congestive heart failure (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Only one trial reported cardiac revascularisation (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Two trials reported peripheral revascularisation (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Six trials reported intervention failure (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). No trials reported lactic acidosis, amputation of lower extremity or socioeconomic effects. </p> <p>All but four of the trials provided a definition of endpoint measurement for at least one of our primary outcomes (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>) (see <a href="./appendices#CD012906-sec-0223">Appendix 15</a>). </p> </section> </section> <section id="CD012906-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded 107 studies described in 114 references after evaluation of the full publication/record.</p> <p>The main reasons for exclusion were: the duration of the intervention was less than one year (28 records); the study was not a RCT (25 records); the reference was a systematic review/meta‐analysis/HTA report (22 records); the intervention was not of interest to the review (22 records); the population was not of interest to the review (eight records) and the study investigated a non‐approved drug (two records). We identified another study from the FDA (trial number MET/D/86/BERGI) (<a href="./references#CD012906-bbs2-0174" title="FDA. FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Assessed 20th September 2019.">FDA 1994</a>). This study compared metformin with diet and had a two‐year duration. However, it is unclear from the FDA document whether this study was randomised and how many participants were included. Weight was the only reported outcome. Therefore, we excluded this study (<a href="./references#CD012906-bbs2-0174" title="FDA. FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Assessed 20th September 2019.">FDA 1994</a>). </p> <p>In three cases we contacted the authors of the study for clarification and received an answer confirming the exclusion of the study (<a href="./references#CD012906-bbs2-0040" title="ChiCTR-IPR-17010825. GLP-1 receptor agonists improvement of constitution in overweight and obese patients with T2DM. www.chictr.org.cn/showprojen.aspx?proj=17806 (first registered 9 March 2017). ">ChiCTR‐IPR‐17010825</a>; <a href="./references#CD012906-bbs2-0046" title="ChiCTR-TRC-12002505. Study of the relationship between blood glucose fluctuation and metformin: a random-controlled study. www.chictr.org.cn/hvshowproject.aspx?id=3572 (date of first registration not reported). ">ChiCTR‐TRC‐12002505</a>; <a href="./references#CD012906-bbs2-0038" title="ChiCTR-IOR-16009296. The effect of Jinlida granule on glycemic excursion and metabonomics in type 2 diabetic patients. www.chictr.org.cn/showprojen.aspx?proj=15637 (first registered 29 September 2016). ">ChiCTR‐IOR‐16009296</a>). In three cases we contacted the authors of the study for clarification and did not receive a reply (<a href="./references#CD012906-bbs2-0040" title="ChiCTR-IPR-17010825. GLP-1 receptor agonists improvement of constitution in overweight and obese patients with T2DM. www.chictr.org.cn/showprojen.aspx?proj=17806 (first registered 9 March 2017). ">ChiCTR‐IPR‐17010825</a>; <a href="./references#CD012906-bbs2-0072" title="JPRN-UMIN000004367. The efficacy of pioglitazone in reduction of urinary albumin excretion in type 2 diabetic patients with microalbuminuria. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005219 (first registered 12 October 2010). ">JPRN‐UMIN000004367</a>; <a href="./references#CD012906-bbs2-0076" title="JPRN-UMIN000001997. Effects of pioglitazone or metformin on bone markers and bone mineral density as well as parameters of atherosclerosis in patients with type 2 diabetes. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002434 (first registered 22 May 2009). KanazawaI , YamaguchiT , YanoS , YamamotoM , YamauchiM , KuriokaS , et al. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int2010;21:2013-8. ">Kanazawa 2009</a>). However, after finding additional information on these trials, we were able to exclude them. </p> <p>For further details, see '<a href="./references#CD012906-sec-0241" title="">Characteristics of excluded studies</a>'. </p> </section> </section> <section id="CD012906-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias of the included trials see <a href="./references#CD012906-sec-0240" title="">Characteristics of included studies</a> table. </p> <p>For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials see <a href="#CD012906-fig-0002">Figure 2</a> and <a href="#CD012906-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012906-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012906-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <div class="figure" id="CD012906-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials)" data-id="CD012906-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials) </p> </div> </div> </div> <section id="CD012906-sec-0067"> <h4 class="title">Allocation</h4> <p>We judged seven trials to be of low risk of bias regarding random sequence generation and allocation concealment (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). We judged three trials to be of low risk of bias regarding the method of random sequence generation and of unclear risk of bias for method of allocation concealment due to inadequate description of allocation concealment (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). We judged the remaining eight trials to be of unclear risk of bias for both the method of random sequence generation and allocation concealment due to the trials only being described as randomised with no further description. </p> <p>We also evaluated study baseline data to incorporate assessment of baseline imbalance into the risk of selection bias. All trials reported only some of our key prognostic variables. However, we did not identify any important baseline imbalances in the studies. Therefore, all of our original assessments of risk of selection bias remained the same after evaluating study baseline data. </p> </section> <section id="CD012906-sec-0068"> <h4 class="title">Blinding</h4> <p>Eight trials were double‐blinded for participants and personnel (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). No trials were single‐blinded only for participants. Seven trials had an open‐label design (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). The remaining three trials did not report blinding procedures. </p> <p>Eight trials were blinded for outcome assessors (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). The remaining trials did not blind or did not report blinding of outcome assessors. </p> <p>Health‐related quality of life was only reported in one trial (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). This trial was not blinded, and as the outcome is self‐reported, we classified it as high risk of bias. Cardiovascular mortality and non‐fatal stroke were adjudicated outcome measurements in one trial (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>), and non‐fatal myocardial infarction was an adjudicated outcome measurement in two trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). For all other trials, these and the remaining outcomes were explicitly stated as or assumed to be investigator‐assessed outcomes. </p> <p>We judged health‐related quality of life to be of high risk of performance and detection bias, since the one study that reported the self‐reported outcome was open‐labelled. For all other outcomes, we judged all trials to be of low risk of performance and detection bias, since we did not judge these investigator‐ or adjudicated‐assessed outcomes to be influenced by a potential lack of blinding. </p> </section> <section id="CD012906-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Losses to follow‐up were present in 13 trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>), and attrition rates ranged from approximately 44% (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) to 95% (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>). Two trials reported no losses to follow‐up (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). Three trials did not describe whether there were losses to follow‐up (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). </p> <p>Intention‐to‐treat analysis was used in seven trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). Of these trials, two trials used last‐observation‐carried forward (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>), and the remaining trials did not report on how missing data were handled. Per‐protocol analysis was used in three trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). The type of analysis was not reported in the remaining eight trials. </p> <p>Of the 13 trials in which losses to follow‐up were present, eight trials had a detailed description of reasons for participants’ withdrawal (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). One trial (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>) had a detailed description of participants’ withdrawal in the first 52 weeks of intervention, but no description in the extension period. The remaining trials did not provide a detailed description. </p> <p>We judged the following outcomes to be of low risk of attrition bias in one or more trials: all‐cause mortality (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) and cardiovascular mortality (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). We judged serious adverse events to be of low risk of attrition bias in two trials (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>) and at high risk in nine trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>We judged the following outcomes to be of unclear or high risk of attrition bias in one or more trials: health‐related quality of life (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>), non‐fatal myocardial infarction (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>), non‐fatal stroke (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) and severe hypoglycaemia (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>The reasons for judging an outcome to be of high risk of attrition bias in a trial included one or more of the following: high dropout rate; dropout rate not balanced between intervention arms; low percentage of participants included in the analysis; inappropriate type of analysis performed (e.g. per protocol); reasons for loss to follow‐up not balanced between intervention arms; inappropriate method of imputing missing data (e.g. last‐observation‐carried‐forward); the proportion of missing outcomes compared with the observed event risk was enough to induce clinically relevant bias in the intervention effect estimate. </p> </section> <section id="CD012906-sec-0070"> <h4 class="title">Selective reporting</h4> <p>A trial protocol was available for seven trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>We judged all but three of the trials to be of high risk of reporting bias for one or more outcome of interest for this review (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). </p> <p>We judged the following primary outcomes to be of high risk of selective outcome reporting bias in one or more trials: all‐cause mortality (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>), health‐related quality of life (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>) and serious adverse events (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>We judged the following secondary outcomes to be of high risk of selective outcome reporting bias in one or more trials: non‐fatal myocardial infarction (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>), cardiovascular mortality, non‐fatal stroke, end‐stage renal disease, blindness (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>) and severe hypoglycaemia (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>For details on the assessment of risk of reporting bias, see ‘<a href="./references#CD012906-sec-0240" title="">Characteristics of included studies</a>’, <a href="./appendices#CD012906-sec-0216">Appendix 8</a>; <a href="./appendices#CD012906-sec-0217">Appendix 9</a>; <a href="./appendices#CD012906-sec-0221">Appendix 13</a> and <a href="./appendices#CD012906-sec-0222">Appendix 14</a>. </p> </section> <section id="CD012906-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 16 trials to be at unclear risk of funding bias due to either having received grants from a pharmaceutical company or not adequately describing sources of funding (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). We judged one trial to be at high risk of funding bias due to all authors being employees and stockholders of a pharmaceutical manufacturer funding the study and performing the concept, design, data analysis and write‐up (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). We judged one trial to be at low risk of funding bias due to having received grants only from a university (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>). </p> </section> </section> <section id="CD012906-sec-0072"> <h3 class="title" id="CD012906-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD012906-tbl-0001"><b>Summary of findings 1</b> Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus insulin</a>; <a href="./full#CD012906-tbl-0002"><b>Summary of findings 2</b> Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus sulphonylureas</a>; <a href="./full#CD012906-tbl-0003"><b>Summary of findings 3</b> Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus thiazolidinediones</a>; <a href="./full#CD012906-tbl-0004"><b>Summary of findings 4</b> Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus dipeptidyl‐peptidase 4 inhibitors</a>; <a href="./full#CD012906-tbl-0005"><b>Summary of findings 5</b> Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus glucagon like peptide‐1 analogues</a>; <a href="./full#CD012906-tbl-0006"><b>Summary of findings 6</b> Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus meglitinides</a> </p> <p>For more details please see <a href="./full#CD012906-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012906-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012906-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012906-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012906-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012906-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD012906-sec-0073"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD012906-sec-0219">Appendix 11</a> and <a href="./appendices#CD012906-sec-0220">Appendix 12</a>. </p> </section> <section id="CD012906-sec-0074"> <h4 class="title">Metformin monotherapy versus placebo</h4> <p>We did not identify any trials comparing metformin monotherapy with placebo.</p> </section> <section id="CD012906-sec-0075"> <h4 class="title">Metformin monotherapy versus no intervention</h4> <p>We identified two trials comparing metformin monotherapy with no intervention (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). Metformin was administered in doses ranging from 850 mg/day to 1700 mg/day and 'no intervention' did not use any glucose‐lowering drug or placebo. With the exception of HbA1c, subgroup and sensitivity analyses were not possible due to a lack of data. </p> <section id="CD012906-sec-0076"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0077"> <h6 class="title">All‐cause mortality</h6> <p>One trial reported all‐cause mortality (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). In the metformin group, 0/16 participants died compared with 0/15 participants in the no intervention group (very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0078"> <h6 class="title">Serious adverse events</h6> <p>One trial reported serious adverse events (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). In the metformin group, 0/16 participants experienced a serious adverse event compared with 0/15 participants in the no intervention group (very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0079"> <h6 class="title">Health‐related quality of life</h6> <p>Neither of the trials reported health‐related quality of life.</p> </section> </section> <section id="CD012906-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0081"> <h6 class="title">Cardiovascular mortality</h6> <p>One trial reported cardiovascular mortality (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). In the metformin group, 0/16 participants died of cardiovascular reasons compared with 0/15 participants in the no intervention group (very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0082"> <h6 class="title">Non‐fatal myocardial infarction, non‐fatal stroke, end‐stage renal disease, blindness, severe hypoglycaemia </h6> <p>Neither of the included trials reported these outcomes.</p> </section> </section> <section id="CD012906-sec-0083"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0084"> <h6 class="title">Anthropometric measures: body mass index (BMI)</h6> <p>One trial reported BMI (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). In the metformin group, the mean BMI was 30.7 kg/m<sup>2</sup> (standard deviation (SD) 3.7) in 16 participants compared with 29.6 kg/m<sup>2</sup> (SD 3.2) in 15 participants in the no intervention group. </p> </section> <section id="CD012906-sec-0085"> <h6 class="title">Anthropometric measures: body weight</h6> <p>One of the trials reported body weight (<a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). In the metformin group, the mean body weight was 85.1 kg (SD 10) in 25 participants compared with 81.0 kg (SD 11.7) in 29 participants in the no intervention group. </p> </section> <section id="CD012906-sec-0086"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>One trial reported on FPG (<a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). In the metformin group, the mean FPG was 6.4 mmol/L (SD 0.6) in 16 participants compared with 6.6 mmol/L (SD 1.0) in 15 participants in the no intervention group. </p> </section> <section id="CD012906-sec-0087"> <h6 class="title">Glycaemic control: HbA1c The figures for the confidence intervals have been rounded up, and the number of participants refers only to the ‘No intervention group. </h6> <p>Both of the included trials reported on HbA1c (mean difference (MD) ‐0.1%, 95% confidence interval (CI) ‐0.5 to 0.4; P = 0.81; 2 trials; 85 participants; <a href="./references#CD012906-fig-0004" title="">Analysis 1.1</a>). </p> <p>Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.67; <a href="./references#CD012906-fig-0005" title="">Analysis 1.2</a>). Testing for subgroup difference according to obesity or presence of selection bias was not possible due to lack of data and both trials having an unclear risk of selection bias. </p> </section> <section id="CD012906-sec-0088"> <h6 class="title">Intervention failure</h6> <p>One trial reported on intervention failure (<a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>). In the metformin group, 0/50 participants experienced intervention failure compared with 4/50 participants (8.0%) in the no intervention group. </p> </section> <section id="CD012906-sec-0089"> <h6 class="title">Lactic acidosis, amputation of lower extremity, congestive heart failure, cardiac revascularisation, peripheral revascularisation, socioeconomic effects </h6> <p>Neither of the included trials reported these outcomes.</p> </section> </section> </section> <section id="CD012906-sec-0090"> <h4 class="title">Metformin monotherapy versus diet</h4> <p>We did not identify any trials comparing metformin monotherapy versus diet.</p> </section> <section id="CD012906-sec-0091"> <h4 class="title">Metformin monotherapy versus insulin</h4> <p>We identified two trials comparing metformin monotherapy with insulin (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). Metformin was administered in doses ranging from 2500 mg/day to 2550 mg/day and insulin was administered in variable doses. One trial reported that 30 participants (8.7%) in the metformin group and 90 participants (30%) in the insulin group did not take the allocated medication either due to refusal of taking the medication or experiencing adverse effects after three years of the intervention (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>).<br/>Subgroup and sensitivity analyses were not possible due to a lack of data. </p> <section id="CD012906-sec-0092"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0093"> <h6 class="title">All‐cause mortality or serious adverse events</h6> <p>Neither of the trials reported all‐cause mortality or serious adverse events.</p> </section> <section id="CD012906-sec-0094"> <h6 class="title">Health‐related quality of life</h6> <p>One trial reported health‐related quality of life for both mental health and physical health measured using the SF‐36 version 2 questionnaire (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>), for details see <a href="./appendices#CD012906-sec-0229">Appendix 21</a>. The mean mental health in the metformin group was 36.4 (SD 7.9) in 46 participants compared with 33.9 (SD 8.6) in 45 participants in the insulin group (very low‐certainty evidence). The mean physical health in the metformin group was 38.1 (SD 5.4) in 46 participants compared with 38.1 (SD 5.3) in 45 participants in the insulin group (very low‐certainty evidence). </p> </section> </section> <section id="CD012906-sec-0095"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0096"> <h6 class="title">Severe hypoglycaemia</h6> <p>One trial reported severe hypoglycaemia (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). In the metformin group, 1/342 participants (0.3%) experienced severe hypoglycaemia compared with 1/409 participants (0.2%) in the insulin group. Data were reported after one year of follow‐up. However, it was not clearly described how many participants were included in the analysis. Unfortunately, the UKPDS 34 did not report the number of participants with hypoglycaemia in each of the intervention arms at the end of the follow‐up period. </p> </section> <section id="CD012906-sec-0097"> <h6 class="title">Cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, end‐stage renal disease or blindness </h6> <p>Neither of the trials reported these outcomes.</p> </section> </section> <section id="CD012906-sec-0098"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0099"> <h6 class="title">Anthropometric measures: body mass index (BMI)</h6> <p>One trial reported BMI (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). In the metformin group, the mean BMI was 29.6 kg/m<sup>2</sup> (SD 5.2) in 46 participants compared with 32.1 kg/m<sup>2</sup> (SD 6.5) in 45 participants in the insulin group. </p> </section> <section id="CD012906-sec-0100"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>One trial reported FPG (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). In the metformin group, the mean FPG was 7.7 mmol/L (SD 2.1) in 262 participants compared with 7.0 mmol/L (SD 2.1) in 304 participants in the insulin group. </p> </section> <section id="CD012906-sec-0101"> <h6 class="title">Glycaemic control: HbA1c</h6> <p>One trial reported HbA1c (<a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>). In the metformin group, the mean HbA1c was 7.1% (SD 0.6) in 46 participants compared with 8.1% (SD 0.9) in 45 participants in the insulin group. </p> </section> <section id="CD012906-sec-0102"> <h6 class="title">Intervention failure</h6> <p>One trial reported on intervention failure (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). In the metformin group, 25/342 participants (7.3%) experienced intervention failure compared with 38/409 participants (9.3%) in the insulin group. Data were reported after three years of the intervention. </p> </section> <section id="CD012906-sec-0103"> <h6 class="title">Anthropometric measures: body weight, lactic acidosis, amputation of lower extremity, congestive heart failure, cardiac revascularisation, peripheral revascularisation, socioeconomic effects </h6> <p>Neither of the included trials reported these outcomes.</p> </section> </section> </section> <section id="CD012906-sec-0104"> <h4 class="title">Metformin monotherapy versus sulphonylureas</h4> <p>We identified seven trials comparing metformin monotherapy with sulphonylureas (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Metformin was administered in doses ranging from 750 mg/day to 3000 mg/day. Sulphonylureas were administered as glibenclamide in two trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>) in doses ranging from 15 mg/day to 20 mg/day; gliclazide in one trial (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>) in a dose of 120 mg/day; glipizide in one trial (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>) in a dose of 30 mg/day; and glimepiride in three trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) in doses ranging from 1 mg/day to 8 mg/day. </p> <section id="CD012906-sec-0105"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0106"> <h6 class="title">All‐cause mortality</h6> <p>Four trials (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) reported all‐cause mortality (very low‐certainty evidence). Three trials reported that 0/24, 0/75 and 0/19 participants in the metformin group died compared with 0/24, 0/73 and 0/19 participants in the sulphonylurea group, respectively (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>). In the remaining trial in the metformin group, 31/1454 participants (2.1%) died compared with 31/1441 participants (2.2%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0107"> <h6 class="title">Serious adverse events</h6> <p>Three trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) reported serious adverse events (very low‐certainty evidence). Two trials reported that 0/75 and 0/19 participants in the metformin group experienced a serious adverse event compared with 0/73 and 0/19 participants in the sulphonylurea group, respectively (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>). In the remaining trial in the metformin group, 331/1454 participants (22.8%) experienced a serious adverse event compared with 308/1441 participants (21.4%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> <p>One trial reported that 30 participants (8.7%) in the metformin group and 16 participants (8%) in the sulphonylurea group did not take the allocated medication either due to refusal of taking the medication or experiencing adverse effects after three years of the intervention (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). </p> </section> <section id="CD012906-sec-0108"> <h6 class="title">Health‐related quality of life</h6> <p>None of the trials reported on this outcome.</p> </section> </section> <section id="CD012906-sec-0109"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0110"> <h6 class="title">Cardiovascular mortality</h6> <p>Two trials (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) reported cardiovascular mortality (very low‐certainty evidence). One trial reported that 0/19 in the metformin group died of cardiovascular reasons compared with 0/19 in the sulphonylurea group (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>). In the other trial in the metformin group, 4/1455 participants (0.3%) died of cardiovascular reasons compared with 8/1447 participants (0.6%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0111"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Three trials (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported non‐fatal myocardial infarction (very low‐certainty evidence). Two trials reported that 0/19 and 0/37 in the metformin group experienced a non‐fatal myocardial infarction compared with 0/19 and 0/34 in the sulphonylurea group (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). In the remaining trial in the metformin group, 21/1454 participants (1.4%) compared with 15/1441 participants (1.0%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0112"> <h6 class="title">Non‐fatal stroke</h6> <p>One of the trials (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported non‐fatal stroke (very low‐certainty evidence). In the metformin group, 0/37 participants experienced a non‐fatal stroke compared with 0/34 participants in the sulphonylurea group. </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0113"> <h6 class="title">Severe hypoglycaemia</h6> <p>Four trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>) reported that a total of 13 participants experienced severe hypoglycaemia: in the metformin group 2/1890 participants (0.1%) experienced severe hypoglycaemia compared with 11/1810 participants (0.6%) in the sulphonylurea group (RR 0.18 in favour of metformin, 95% CI 0.04 to 0.82; P = 0.03; 4 trials; 3700 participants; <a href="./references#CD012906-fig-0006" title="">Analysis 2.1</a>). The 95% prediction interval did not provide a meaningful estimate. </p> <p>For one of the trials data were reported after one year of follow‐up, and the number of participants included in the analysis was not clearly described (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). Unfortunately, the UKPDS 34 did not report the number of participants with hypoglycaemia in each of the intervention arms at the end of the follow‐up period. </p> <p>Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.62; <a href="./references#CD012906-fig-0007" title="">Analysis 2.2</a>). Testing for subgroup differences according to sulphonylurea generation, obesity or presence of selection bias was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials did not substantially affect the effect estimate (RR 0.12, 95% CI 0.02 to 0.99; P = 0.05) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding and were based in different countries. </p> </section> <section id="CD012906-sec-0114"> <h6 class="title">End‐stage renal disease or blindness</h6> <p>None of the included trials reported on these outcomes.</p> </section> </section> <section id="CD012906-sec-0115"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0116"> <h6 class="title">Anthropometric measures: body mass index (BMI)</h6> <p>Four trials reported BMI (MD 0.6 kg/m<sup>2</sup> in favour of sulphonylureas, 95% CI 0.3 to 0.9; P &lt; 0.001; 4 trials; 461 participants; <a href="./references#CD012906-fig-0008" title="">Analysis 2.3</a>) (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>Testing for subgroup differences according to sulphonylurea generation did not indicate an interaction (P = 0.85; <a href="./references#CD012906-fig-0008" title="">Analysis 2.3</a>). Testing for subgroup differences according to duration of follow‐up, presence of selection bias or obesity was not possible due to a lack of data. </p> <p>The effect estimate was greatly influenced by the large weight of one trial (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>). Sensitivity analysis showed that excluding this trial substantially affected the effect estimate (MD 0.02 kg/m<sup>2</sup>, 95% CI ‐1.04 to 1.08; P = 0.98; 3 trials; 313 participants). This was most likely due to the slight baseline imbalances in BMI between the metformin and sulphonylurea group coupled with the considerably smaller variance in the results of this trial compared to the other trials in the meta‐analysis. Sensitivity analyses based on very long or large trials, publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were of short duration (less than two years), published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> </section> <section id="CD012906-sec-0117"> <h6 class="title">Anthropometric measures: body weight</h6> <p>Four of the trials reported on body weight (MD ‐3.9 kg in favour of metformin, 95% CI ‐5.2 to ‐2.5; P &lt; 0.001; 4 trials; 3185 participants; <a href="./references#CD012906-fig-0009" title="">Analysis 2.4</a>) (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>). Two of the trials reported the effect size as change from baseline (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Testing for subgroup differences according to sulphonylurea generation indicated an interaction (P = 0.002; <a href="./references#CD012906-fig-0009" title="">Analysis 2.4</a>). For second‐generation sulphonylurea the effect estimate (MD ‐4.5 kg, 95% CI ‐5.2 to ‐3.9; P &lt; 0.001; 3 trials; 2981 participants) was in favour of metformin. For third‐generation sulphonylurea the effect estimate (MD ‐2.1 kg, 95% CI ‐3.5 to ‐0.6; P = 0.005; 1 trial; 204 participants) was also in favour of metformin. Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.42) (<a href="./references#CD012906-fig-0010" title="">Analysis 2.5</a>). Testing for subgroup differences according to presence of selection bias yielded the same subgroups and results as the subgroup analysis according to duration of follow‐up. Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting the analysis to very long or large trials did not substantially affect the effect estimate (MD ‐4.5 kg, 95% CI ‐5.3 to ‐3.7; P &lt; 0.001; 1 trial; 2895 participants) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding and were based in different countries. </p> <p>We detected substantial statistical heterogeneity between the trials (P = 0.02, I<sup>2</sup> = 69%). This could have been due to different types of comparator used (gliclazide, glipizide, glibenclamide, glimepiride), different doses of metformin (ranging from 2000 mg/day to 3000 mg/day), or different length of follow‐up (ranging from one year to four years) across the trials. </p> </section> <section id="CD012906-sec-0118"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>All trials reported FPG (random‐effects MD ‐0.23 mmol/L, 95% CI ‐0.54 to 0.07; P = 0.13; fixed‐effect MD ‐0.27 mmol/L in favour of metformin, 95% CI ‐0.41 to ‐0.14; P &lt; 0.001; 7 trials; 3878 participants; <a href="./references#CD012906-fig-0011" title="">Analysis 2.6</a>). One of the trials reported data after three years of follow‐up (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). One trial reported FPG in both a published paper and a FDA document (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). In the publication, a total of 48 participants were included in the analysis. In the FDA report only 43 participants were included in the analysis. In the data from the FDA report, a larger reduction in FPG with glipizide was reported than reported in the published paper (2.8 mmol/L versus 3.2 mmol/L). In the FDA report it was concluded that metformin and glipizide were equally effective. In the published paper it was concluded that metformin gave greater reduction in FPG (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). </p> <p>Testing for subgroup differences according to sulphonylurea generation did not indicate an interaction (P = 0.17; <a href="./references#CD012906-fig-0011" title="">Analysis 2.6</a>). Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.21; <a href="./references#CD012906-fig-0012" title="">Analysis 2.7</a>). Testing for subgroup differences according to presence of selection bias yielded the same subgroups and results as the subgroup analysis according to duration of follow‐up. Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials did not substantially affect the effect estimate (MD ‐0.35 mmol/L in favour of metformin, 95% CI ‐0.51 to ‐0.19; P &lt; 0.001; 1 trial; 2895 participants) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> <p>We detected substantial statistical heterogeneity (P = 0.01, I<sup>2</sup> = 65%). This could have been due to different types of comparator used (gliclazide, glipizide, glibenclamide, glimepiride), different doses of intervention (ranging from 750 mg/day to 3000 mg/day), or comparator (ranging from 15 mg/day to 20 mg/day for glibenclamide and ranging from 2 mg/day to 8 mg/day for glimepiride) or different length of follow‐up (ranging from one year to four years) across the trials. </p> </section> <section id="CD012906-sec-0119"> <h6 class="title">Glycaemic control: HbA1c</h6> <p>Six trials reported HbA1c (random‐effects MD ‐0.2%, 95% CI ‐0.5 to 0.02; P = 0.08; fixed‐effect MD ‐0.2% in favour of metformin, 95% CI ‐0.3 to ‐0.1; P &lt; 0.001; 6 trials; 3404 participants; <a href="./references#CD012906-fig-0013" title="">Analysis 2.8</a>) (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>One trial reported HbA1c in both a published paper and a FDA document (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). In the publication, a total of 48 participants were included in the analysis. In the FDA report only 43 participants were included in the analysis. In the FDA report it was concluded that there was a greater reduction in HbA1c with metformin, although this was not statistically significant. SD and number of participants in each intervention arm were not reported (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). </p> <p>Testing for subgroup differences according to sulphonylurea generation indicated an interaction (P = 0.02; <a href="./references#CD012906-fig-0013" title="">Analysis 2.8</a>). For second‐generation sulphonylurea the effect estimate (MD ‐0.5%, 95% CI ‐0.9 to ‐0.1; P = 0.01; 3 trials; 2981 participants) was in favour of metformin. For third‐generation sulphonylurea the effect estimate (MD 0.1%, 95% CI ‐0.2 to 0.3; P = 0.64; 3 trials; 423 participants) was not in favour of either intervention. However, the CIs overlapped to a small degree indicating doubtful subgroup differences. </p> <p>Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.98; <a href="./references#CD012906-fig-0014" title="">Analysis 2.9</a>). Testing for subgroup differences according to presence of selection bias yielded the same subgroups and results as the subgroup analysis according to duration of follow‐up. Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials substantially affected the effect estimate (MD ‐0.24 in favour of metformin, 95% CI ‐0.35 to ‐0.13; P &lt; 0.0001; 1 trials; 2895 participants) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible, since all the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> </section> <section id="CD012906-sec-0120"> <h6 class="title">Congestive heart failure</h6> <p>Three trials reported congestive heart failure (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). However, two trials reported that 0/19 and 0/37 participants in the metformin group experienced congestive heart failure compared with 0/19 and 0/34 participants in the sulphonylurea group, respectively (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). In the remaining trial, 19/1454 participants (1.3%) in the metformin group experienced congestive heart failure compared with 9/1441 participants (0.6%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0121"> <h6 class="title">Cardiac revascularisation</h6> <p><a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a> reported cardiac revascularisation. In the metformin group, 0/37 participants experienced cardiac revascularisation compared with 0/34 participants in the sulphonylurea group. </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0122"> <h6 class="title">Peripheral revascularisation</h6> <p>Two trials reported peripheral revascularisation (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a> reported that in the metformin group 0/37 participants experienced peripheral revascularisation compared with 0/34 in the sulphonylurea group. In the remaining trial, 27/1454 participants (1.9%) in the metformin group experienced peripheral revascularisation compared with 31/1441 participants (2.2%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analyses were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0123"> <h6 class="title">Intervention failure</h6> <p>Three trials reported that a total of 576 participants experienced intervention failure: in the metformin group 233/1835 participants (12.7%) experienced intervention failure compared with 343/1755 participants (19.5%) in the sulphonylurea group (RR 0.66 in favour of metformin, 95% CI 0.57 to 0.77; P &lt; 0.001; 3 trials; 3590 participants; <a href="./references#CD012906-fig-0015" title="">Analysis 2.10</a>) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) . In one trial (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>), data were reported after three years of follow‐up. In one trial the analysis included withdrawals that were excluded from the other analyses from the trial (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>Testing for subgroup differences according to sulphonylurea generation did not indicate an interaction (P = 0.36; <a href="./references#CD012906-fig-0015" title="">Analysis 2.10</a>). Testing for subgroup differences according to duration of follow‐up or presence of selection bias yielded the same subgroups and results as the subgroup analysis according to sulphonylurea generation (<a href="./references#CD012906-fig-0016" title="">Analysis 2.11</a>). Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials did not substantially affect the effect estimate (RR 0.66, 95% CI 0.56 to 0.77; P &lt; 0.001; 1 trial; 2895 participants) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding and were based in different countries. </p> </section> <section id="CD012906-sec-0124"> <h6 class="title">Lactic acidosis, amputation of lower extremity, socioeconomic effects</h6> <p>None of the included trials reported these outcomes.</p> </section> </section> </section> <section id="CD012906-sec-0125"> <h4 class="title">Metformin monotherapy versus thiazolidinediones</h4> <p>We identified seven trials comparing metformin monotherapy versus thiazolidinediones (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). Metformin was administered in doses ranging from 750 mg/day to 3000 mg/day. Thiazolidinediones were administered as pioglitazone in four trials (<a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) in doses of 45 mg/day and as rosiglitazone in three trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) in doses ranging from 4 mg/day to 8 mg/day. </p> <section id="CD012906-sec-0126"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0127"> <h6 class="title">All‐cause mortality</h6> <p>Five trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>) reported that a total of 71 participants died: in the metformin group 33/2197 participants (1.5%) died compared with 38/2205 participants (1.7%) in the thiazolidinedione group (RR 0.88, 95% CI 0.55 to 1.39; P = 0.57; 5 trials; 4402 participants; very low‐certainty evidence; <a href="./references#CD012906-fig-0017" title="">Analysis 3.1</a>) The 95% prediction interval ranged between 0.42 and 1.85. </p> <p>In two trials there were no deaths (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>), and one trial contributed 65/71 events (91.5%) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type did not indicate an interaction (P = 0.76). Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.57; <a href="./references#CD012906-fig-0018" title="">Analysis 3.2</a>). Testing for subgroup differences according to presence of selection bias or obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) did not substantially affect the effect estimate (RR 0.91, 95% CI 0.56 to 1.48; P = 0.71; 1 trial; 2910 participants). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> </section> <section id="CD012906-sec-0128"> <h6 class="title">Serious adverse events</h6> <p>Four trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) reported that a total of 689 participants experienced a serious adverse event: in the metformin group 336/1600 participants (21.0%) experienced a serious adverse event compared with 353/1608 participants (22.0%) in the thiazolidinedione group (RR 0.95, 95% CI 0.84 to 1.09; P = 0.49; 4 trials; 3208 participants; very low‐certainty evidence; <a href="./references#CD012906-fig-0019" title="">Analysis 3.3</a>). In two trials no serious adverse events occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type was not possible due to lack of data. Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.64; <a href="./references#CD012906-fig-0020" title="">Analysis 3.4</a>). Testing for subgroup differences according to presence of selection bias or obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) did not substantially affect the effect estimate (RR 0.96, 95%, CI 0.84 to 1.09; P = 0.52; 1 trial; 2910 participants). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding and were based in different countries. </p> </section> <section id="CD012906-sec-0129"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included trials reported on health‐related quality of life.</p> </section> </section> <section id="CD012906-sec-0130"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0131"> <h6 class="title">Cardiovascular mortality</h6> <p>Four trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) reported that a total of 10 participants died of cardiovascular reasons: in the metformin group 4/1601 participants (0.2%) died of cardiovascular reasons compared with 6/1610 participants (0.4%) in the thiazolidinedione group (RR 0.71, 95% CI 0.21 to 2.39; P = 0.58; 4 trials; 3211 participants; very low‐certainty evidence; <a href="./references#CD012906-fig-0021" title="">Analysis 3.5</a>). In two trials no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). </p> <p>Testing for subgroup differences according to duration of follow‐up did not indicate an interaction (P = 0.63: <a href="./references#CD012906-fig-0022" title="">Analysis 3.6</a>). Testing for subgroup differences according to thiazolidinedione type, presence of selection bias or obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials did not substantially affect the effect estimate (RR 0.80, 95% CI 0.22 to 2.98; P = 0.74; 1 trial; 2910 participants) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding, and country were not possible. All the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding and were based in different countries. </p> </section> <section id="CD012906-sec-0132"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Three trials (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported non‐fatal myocardial infarction (very low‐certainty evidence). Two trials reported that 0/19 and 0/37 participants in the metformin group experienced a non‐fatal myocardial infarction compared with 0/19 and 0/35 participants in the thiazolidinedione group, respectively (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). In the remaining trial (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>), 21/1454 participants (1.4%) in the metformin group experienced non‐fatal myocardial infarction compared with 25/1456 participants (1.7%) in the thiazolidinedione group. </p> <p>Subgroup and sensitivity analysis could not be performed due to lack of data.</p> </section> <section id="CD012906-sec-0133"> <h6 class="title">Non‐fatal stroke</h6> <p>One trial (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported non‐fatal stroke. In the metformin group, 0/37 participants experienced non‐fatal stroke compared with 0/35 participants in the thiazolidinedione group (very low‐certainty evidence). </p> <p>Subgroup and sensitivity analysis could not be performed due to lack of data.</p> </section> <section id="CD012906-sec-0134"> <h6 class="title">Severe hypoglycaemia</h6> <p>Two trials reported severe hypoglycaemia (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a> reported that 0/19 participants in the metformin group experienced severe hypoglycaemia compared with 0/19 participants in the thiazolidinedione group. In the remaining trial in the metformin group, 1/1454 participants (0.1%) experienced severe hypoglycaemia compared with 1/1456 (0.1%) in the thiazolidinedione group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analysis could not be performed due to lack of data.</p> </section> <section id="CD012906-sec-0135"> <h6 class="title">End‐stage renal disease or blindness</h6> <p>None of the included trials reported these outcomes.</p> </section> </section> <section id="CD012906-sec-0136"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0137"> <h6 class="title">Anthropometric measures: body mass index (BMI)</h6> <p>Three trials (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported BMI (MD ‐0.4 kg/m<sup>2</sup>, 95% CI ‐2.3 to 1.6; P = 0.69; 3 trials; 145 participants; <a href="./references#CD012906-fig-0023" title="">Analysis 3.7</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type did not indicate an interaction (P = 0.48). Testing for subgroup differences according to duration of follow‐up, presence of selection bias, or obesity was not possible due to a lack of data. </p> <p>Sensitivity analyses based on very long or large trials, publication status, language of publication, diagnostic criteria, source of funding and country were not possible, since all the trials had less than 1000 participants, were of one year duration, were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> </section> <section id="CD012906-sec-0138"> <h6 class="title">Anthropometric measures: body weight</h6> <p>Two trials (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) reported body weight (random‐effects MD ‐1.3 kg, 95% CI ‐15.2 to 12.7; P = 0.86; fixed‐effect MD ‐7.6 kg in favour of metformin, 95% CI ‐8.3 to ‐6.9; P &lt; 0.001; 2 trials; 2948 participants; <a href="./references#CD012906-fig-0024" title="">Analysis 3.8</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type indicated an interaction (P = 0.002). For pioglitazone the effect estimate (MD 6.6 kg, 95% CI ‐2.3 to 15.5; P = 0.15; 1 trial; 38 participants) was not in favour of either intervention. For rosiglitazone the effect estimate (MD ‐7.7 kg, 95% CI ‐8.4 to ‐7.0; P &lt; 0.001; 1 trial; 2910 participants) was in favour of metformin. Testing for subgroup differences according to duration of follow‐up or presence of selection bias yielded the same subgroups and results as the subgroup analysis according to thiazolidinedione type. Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis was not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0139"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>Six trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported FPG (random‐effects MD 0.32 mmol/L, 95% CI ‐0.21 to 0.84; P = 0.23; fixed‐effect MD 0.52 mmol/L in favour of thiazolidinediones, 95% CI 0.38 to 0.65; P &lt; 0.001; 6 trials; 4456 participants; <a href="./references#CD012906-fig-0025" title="">Analysis 3.9</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type did not indicate an interaction (P = 0.25). Testing for subgroup differences according to duration of follow‐up indicated an interaction (P = 0.01; <a href="./references#CD012906-fig-0026" title="">Analysis 3.10</a>). For the one trial of long duration (two years or more) the effect estimate (MD 0.73 mmol/L, 95% CI 0.57 to 0.89; P &lt; 0.001; 1 trial; 2910 participants) was in favour of thiazolidinedione. For trials of short duration (less than two years) the effect estimate (MD 0.12 mmol/L, 95% CI ‐0.32 to 0.56; P = 0.59; 5 trials; 1546 participants) was not in favour of either intervention. Testing for subgroup differences according to presence of selection bias did not indicate an interaction (P = 0.89; <a href="./references#CD012906-fig-0027" title="">Analysis 3.11</a>). Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) substantially affected the effect estimate (MD 0.73 mmol/L in favour of thiazolidinedione, 95% CI 0.57 to 0.89; P &lt; 0.001; 1 trial; 2910 participants). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding, and country were not possible, since all the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding and were based in different countries. </p> <p>We detected considerable heterogeneity between the trials (P &lt; 0.001, I<sup>2</sup> = 85%). This could have been due to different types of comparator used (pioglitazone, rosiglitazone), different doses of intervention (ranging from 750 mg/day to 2550 mg/day) or comparator (ranging from 4 mg/day to 8 mg/day for rosiglitazone) or different length of follow‐up (ranging from one year to four years) across the trials. </p> </section> <section id="CD012906-sec-0140"> <h6 class="title">Glycaemic control: HbA1c</h6> <p>Six trials (<a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported HbA1c (MD 0.01%, 95% CI ‐0.2 to 0.2; P = 0.95; 6 trials; 4456 participants; <a href="./references#CD012906-fig-0028" title="">Analysis 3.12</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type did not indicate an interaction (P = 0.26). Testing for subgroup differences according to duration of follow‐up indicated an interaction (P &lt; 0.001; <a href="./references#CD012906-fig-0029" title="">Analysis 3.13</a>). For the one trial of long duration (two years or more) the effect estimate (MD 0.3%, 95% CI 0.2 to 0.4; P &lt; 0.001; 1 trial; 2910 participants) was in favour of thiazolidinediones. For trials of short duration (less than two years) the effect estimate (MD ‐0.1%, 95% CI ‐0.2 to 0.01; P = 0.07; 5 trials; 1546 participants) was not in favour of either intervention. Testing for subgroup differences according to presence of selection bias did not indicate an interaction (P = 0.65; <a href="./references#CD012906-fig-0030" title="">Analysis 3.14</a>). Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) substantially affected the effect estimate (MD 0.3% in favour of thiazolidinediones, 95% CI 0.2 to 0.4; P &lt; 0.001; 1 trial; 2910 participants). Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible, since all the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> </section> <section id="CD012906-sec-0141"> <h6 class="title">Congestive heart failure</h6> <p>Three trials (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported congestive heart failure. Two trials reported that 0/37 and 0/19 participants in the metformin group experienced congestive heart failure compared with 0/35 and 0/19 participants in the thiazolidinedione group, respectively (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). In the remaining trial, 19/1454 participants (1.3%) in the metformin group experienced congestive heart failure compared with 22/1456 participants (1.5%) in the thiazolidinedione group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type, duration of follow‐up, presence of selection bias, or obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis showed that restricting analysis to very long or large trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) contained the same trial data as in the main analysis. Sensitivity analyses based on publication status, language of publication, diagnostic criteria, source of funding and country were not possible, since all the trials were published in medical journals, published in English, used different or did not report diagnostic criteria, did not have sufficient data on source of funding, and were based in different countries. </p> </section> <section id="CD012906-sec-0142"> <h6 class="title">Cardiac revascularisation</h6> <p>One trial reported cardiac revascularisation (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). In the metformin group, 0/37 participants experienced cardiac revascularisation compared with 0/35 in the thiazolidinedione group. </p> <p>Subgroup and sensitivity analysis could not be performed due to lack of data.</p> </section> <section id="CD012906-sec-0143"> <h6 class="title">Peripheral revascularisation</h6> <p>Two trials reported data peripheral revascularisation (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). One trial reported that 0/37 participants experienced peripheral revascularisation in the metformin group compared with 0/35 participants in the thiazolidinedione group (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). In the remaining trial, 27/1454 participants (1.9%) in the metformin group experienced peripheral revascularisation compared with 36/1456 participants (2.5%) in the thiazolidinedione group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>Subgroup and sensitivity analysis could not be performed due to lack of data.</p> </section> <section id="CD012906-sec-0144"> <h6 class="title">Intervention failure</h6> <p>Two of the included trials (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) reported that a total of 352 participants experienced intervention failure: in the metformin group 208/1493 participants (13.9%) experienced intervention failure compared with 144/1494 participants (9.6%) in the thiazolidinedione group (RR 1.45 in favour of thiazolidinediones, 95% CI 1.18 to 1.77; P &lt; 0.001; 2 trials; 2987 participants; <a href="./references#CD012906-fig-0031" title="">Analysis 3.15</a>). In one trial the results included withdrawals from the study which were excluded in all other analyses (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>Testing for subgroup differences according to thiazolidinedione type did not indicate an interaction (P = 0.78). Testing for subgroup differences according to duration of follow‐up (<a href="./references#CD012906-fig-0032" title="">Analysis 3.16</a>) or presence of selection bias (<a href="./references#CD012906-fig-0033" title="">Analysis 3.17</a>) yielded the same subgroups and results as the subgroup analysis according to thiazolidinedione type. Testing for subgroup differences according to obesity was not possible due to a lack of data. </p> <p>Sensitivity analysis was not possible due to a lack of data</p> </section> <section id="CD012906-sec-0145"> <h6 class="title">Lactic acidosis, amputation of lower extremity, socioeconomic effects</h6> <p>None of the included trials reported these outcomes.</p> </section> </section> </section> <section id="CD012906-sec-0146"> <h4 class="title">Metformin monotherapy versus dipeptidyl peptidase‐4 inhibitors</h4> <p>We identified three trials comparing metformin monotherapy with a dipeptidyl peptidase‐4 inhibitor (DPP‐4 inhibitor) (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). Metformin was administered in doses ranging from 1000 mg/day to 2000 mg/day. DPP‐4 inhibitors were administered as saxagliptin in doses of 10 mg/day in one trial (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>); vildagliptin in doses of 100 mg/day in one trial (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>); and sitagliptin in doses of 100 mg/day (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). In one trial (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>), two doses of metformin were administered in two separate intervention groups. These doses were 1000 mg/day and 2000 mg/day, respectively. For all of the following results these groups were combined as one intervention group. </p> <section id="CD012906-sec-0147"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0148"> <h6 class="title">All‐cause mortality</h6> <p>All of the included trials reported that a total of 15 participants died: in the metformin group 10/944 participants (1.1%) died compared with 5/1033 participants (0.5%) in the DPP‐4 inhibitor group (3 trials; 1977 participants; very low‐certainty evidence; <a href="./references#CD012906-fig-0034" title="">Analysis 4.1</a>). As each trial applied a different DPP‐4 inhibitor it was inappropriate to pool results in a meta‐analysis. For this reason, we also did not perform sensitivity or subgroup analysis. In one trial results were reported after 104 weeks of the intervention (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). In one trial results were calculated using all‐cause mortality from the first 52 weeks of intervention summed with all‐cause mortality from the extension period (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). </p> <p>In the saxagliptin trial, 5/328 (1.5%) participants in the metformin group died compared with 2/335 (0.6%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>). </p> <p>In the sitagliptin trial, 1/364 (0.3%) participants in the metformin group died compared with 0/179 in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>In the vildagliptin trial, 4/252 (1.6%) participants in the metformin group died compared with 3/519 (0.6%) in the vildagliptin group (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). </p> </section> <section id="CD012906-sec-0149"> <h6 class="title">Serious adverse events</h6> <p>All of the included trials reported that a total of 108 participants experienced a serious adverse event: in the metformin group 44/944 participants (4.7%) experienced a serious adverse event compared with 64/1033 participants (6.2%) in the DPP‐4 inhibitor group (3 trials; 1977 participants; very low‐certainty evidence; <a href="./references#CD012906-fig-0035" title="">Analysis 4.2</a>). As each trial applied a different DPP‐4 inhibitor it was inappropriate to pool results in a meta‐analysis. For this reason, we also did not perform sensitivity or subgroup analysis. In one trial results were reported after 52 weeks of intervention (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). In one trial results were reported after 104 weeks of intervention and excluded data for participants who initiated glycaemic rescue therapy (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>In the saxagliptin trial, 15/328 (4.5%) participants in the metformin group experienced a serious adverse event compared with 16/335 (4.8%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>). </p> <p>In the sitagliptin trial, 16/364 (4.4%) participants in the metformin group experienced a serious adverse event compared with 13/179 (7.2%) participants in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>In the vildagliptin trial, 13/252 (5.2%) participants in the metformin group experienced a serious adverse event compared with 35/519 (6.7%) participants in the vildagliptin group (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). </p> </section> <section id="CD012906-sec-0150"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included trials reported on health‐related quality of life.</p> </section> </section> <section id="CD012906-sec-0151"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0152"> <h6 class="title">Cardiovascular mortality</h6> <p>Two trials (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) reported on cardiovascular mortality (very low‐certainty evidence). One trial reported that in the metformin group 0/364 participants died from cardiovascular reasons compared with 0/179 participants in the DPP‐4 inhibitor group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). In the remaining trial, 3/328 participants (0.9%) in the metformin group died from cardiovascular reasons compared with 2/335 participants (0.6%) in the DPP‐4 inhibitor group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>). In <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a> one additional participant in the metformin group died from sudden death which was not classified as cardiovascular mortality. <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a> reported results after 104 weeks of intervention. </p> </section> <section id="CD012906-sec-0153"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>One trial reported non‐fatal myocardial infarction (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). In the metformin group, 1/364 participants (0.3%) experienced a non‐fatal myocardial infarction compared with 0/179 participants in the DPP‐4 inhibitor group (very low‐certainty evidence). Results were reported after 104 weeks of intervention. </p> </section> <section id="CD012906-sec-0154"> <h6 class="title">Non‐fatal stroke</h6> <p>One trial reported non‐fatal stroke (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). In the metformin group, 0/364 participants experienced a non‐fatal stroke compared with 0/179 participants in the DPP‐4 inhibitor group (very low‐certainty evidence). Results were reported after 104 weeks of intervention. </p> </section> <section id="CD012906-sec-0155"> <h6 class="title">Severe hypoglycaemia</h6> <p>All of the included trials reported severe hypoglycaemia. Two trials reported that in the metformin group 0/328 participants and 0/252 participants experienced severe hypoglycaemia compared with 0/335 and 0/519 participants in the DPP‐4 inhibitor group, respectively (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>; <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). In the remaining trial, 3/364 participants (0.8%) in the metformin group experienced severe hypoglycaemia compared with 0/179 participants in the DPP‐4 inhibitor group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a> reported results after 52 weeks of intervention. <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a> reported results after 104 weeks of intervention. </p> </section> <section id="CD012906-sec-0156"> <h6 class="title">End‐stage renal disease or blindness</h6> <p>None of the included trials reported these outcomes.</p> </section> </section> <section id="CD012906-sec-0157"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0158"> <h6 class="title">Anthropometric measures: body weight</h6> <p>All of the included trials reported body weight. However, as each trial applied a different DDP‐4 inhibitor, no meta‐analysis was performed (<a href="./references#CD012906-fig-0036" title="">Analysis 4.3</a>). All trials favoured metformin. In one trial (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>), SD was not reported and had to be imputed by combining the SDs from the two other trials in the analysis. <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a> reported results after 52 weeks of intervention and adjusted for baseline HbA1c values. <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a> reported results after 104 weeks of intervention and excluded participants that required rescue medication in the initial 24 weeks and/or the subsequent 30 weeks of the intervention. <a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a> reported results after 76 weeks of intervention. </p> <p>Sensitivity and subgroup analysis were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0159"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>All of the included trials reported on FPG. However, as each trial applied a different DDP‐4 inhibitor, no meta‐analysis was performed (<a href="./references#CD012906-fig-0037" title="">Analysis 4.4</a>). All studies showed a reduction in FPG in favour of metformin. </p> <p>Sensitivity and subgroup analysis were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0160"> <h6 class="title">Glycaemic control: HbA1c</h6> <p>All of the included trials reported on HbA1c. However, as each trial applied a different DDP‐4 inhibitor, no meta‐analysis was performed (<a href="./references#CD012906-fig-0038" title="">Analysis 4.5</a>). </p> <p>Sensitivity and subgroup analysis were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0161"> <h6 class="title">Intervention failure</h6> <p>One trial reported on intervention failure (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>). In the metformin group, 105/328 participants (32.0%) experienced intervention failure compared with 155/335 participants (46.3%) in the DPP‐4 inhibitor group. </p> <p>Sensitivity and subgroup analysis were not possible due to a lack of data.</p> </section> <section id="CD012906-sec-0162"> <h6 class="title">Lactic acidosis, amputation of lower extremity, congestive heart failure, cardiac revascularisation, peripheral revascularisation, socioeconomic effects </h6> <p>None of the included trials reported these outcomes.</p> </section> </section> </section> <section id="CD012906-sec-0163"> <h4 class="title">Metformin monotherapy versus glucagon like peptide‐1 analogues</h4> <p>One trial compared metformin monotherapy with a glucagon like peptide‐1 analogue (GLP‐1) (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>). Metformin was administered in a doses 1500 mg/day to 2000 mg/day. GLP‐1 was administered as dulaglutide. Two different doses of dulaglutide were administered in the two separate comparator groups. These doses were 0.75 mg/week and 1.5 mg/week, respectively. For all of the following results these groups were combined as one comparator group. </p> <section id="CD012906-sec-0164"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0165"> <h6 class="title">All‐cause mortality</h6> <p>In the metformin group, 0/268 participants died compared with 0/539 participants in the GLP‐1 group (very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0166"> <h6 class="title">Serious adverse events</h6> <p>In the metformin group, 16/268 participants (6.0%) experienced a serious adverse event compared with 35/539 participants (6.5%) in the GLP‐1 group (RR 0.92, 95% CI 0.52 to 1.63; P = 0.77; very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0167"> <h6 class="title">Health‐related quality of life</h6> <p>The included trial did not report health‐related quality of life.</p> </section> </section> <section id="CD012906-sec-0168"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0169"> <h6 class="title">Cardiovascular mortality</h6> <p>In the metformin group, 0/268 participants died of cardiovascular reasons compared with 0/539 participants in the GLP‐1 group (very low‐certainty evidence). The results were reported after 53 weeks of follow‐up. </p> </section> <section id="CD012906-sec-0170"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>In the metformin group, 0/268 participants experienced a non‐fatal myocardial infarction compared with 1/539 participants (0.2%) in the GLP‐1 group (RR 0.67, 95% CI 0.03 to 16.37; P = 0.81; very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0171"> <h6 class="title">Non‐fatal stroke</h6> <p>In the metformin group, 0/268 participants experienced a non‐fatal stroke compared with 1/539 (0.2%) participants in the GLP‐1 group (RR 0.67, 95% CI 0.03 to 16.37; P = 0.81; very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0172"> <h6 class="title">Severe hypoglycaemia</h6> <p>In the metformin group, 0/268 participants experienced severe hypoglycaemia compared with 0/539 participants in the GLP‐1 group. </p> </section> <section id="CD012906-sec-0173"> <h6 class="title">End‐stage renal disease or blindness</h6> <p>The included trial did not report these outcomes.</p> </section> </section> <section id="CD012906-sec-0174"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0175"> <h6 class="title">Anthropometric measures: body mass index (BMI)</h6> <p>In the metformin group, the mean change of baseline BMI was ‐0.8 kg/m<sup>2</sup> (SD 1.8) in 267 participants compared with ‐0.6 kg/m<sup>2</sup> (SD 1.7) in 536 participants in the GLP‐1 group. The result was adjusted for country, prior diabetes‐medication usage, baseline value, visit, treatment‐by‐visit and patient as a random‐effects in a mixed‐effects, repeated measures analysis. </p> </section> <section id="CD012906-sec-0176"> <h6 class="title">Anthropometric measures: body weight</h6> <p>In the metformin group, the mean change of baseline body weight was ‐2.2 kg (SD 4.7) in 267 participants compared with ‐1.5 kg (SD 4.8) in 536 participants in the GLP‐1 group. The result was adjusted for country, prior diabetes‐medication usage, baseline value, visit, treatment‐by‐visit and patient as a random‐effects in a mixed‐effects, repeated measures analysis. </p> </section> <section id="CD012906-sec-0177"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>In the metformin group, the mean change of baseline FPG was ‐1.15 mmol/L (SD 1.95) in 194 participants compared with ‐1.28 mmol/L (SD 2.04) in 417 participants in the GLP‐1 group. The result was adjusted for country, prior diabetes‐medication usage, baseline value, visit, treatment‐by‐visit and patient as a random‐effects in a mixed‐effects, repeated measures analysis. </p> </section> <section id="CD012906-sec-0178"> <h6 class="title">Glycaemic control: HbA1c</h6> <p>In the metformin group, the mean change of baseline HbA1c was ‐0.5% (SD 1.1) in 265 participants compared with ‐0.6% (SD 1.1) in 530 participants in the GLP‐1 group (MD 0.1%, 95% CI ‐0.1 to 0.3; P = 0.1805). The result was adjusted for country, prior diabetes‐medication usage, baseline value, visit, treatment‐by‐visit and patient as a random‐effects in a mixed‐effects, repeated measures analysis. </p> </section> <section id="CD012906-sec-0179"> <h6 class="title">Congestive heart failure</h6> <p>In the metformin group, 1/268 participants (0.4%) experienced congestive heart failure compared with 0/539 participants in the GLP‐1 group. </p> </section> <section id="CD012906-sec-0180"> <h6 class="title">Intervention failure</h6> <p>In the metformin group, 14/268 participants (5.2%) experienced intervention failure compared with 20/539 participants (3.7%) in the GLP‐1 group. </p> </section> <section id="CD012906-sec-0181"> <h6 class="title">Lactic acidosis, amputation of lower extremity, cardiac revascularisation, peripheral revascularisation, socioeconomic effects </h6> <p>The included trial did not report these outcomes.</p> </section> </section> </section> <section id="CD012906-sec-0182"> <h4 class="title">Metformin monotherapy versus meglitinides</h4> <p>We identified one trial comparing metformin monotherapy with meglitinide (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>). Metformin was administered in doses of 1500 mg/day to 2500 mg/day. Meglitinide was administered as repaglinide in doses of 2 mg/day to 4 mg/day. </p> <section id="CD012906-sec-0183"> <h5 class="title">Primary outcomes</h5> <section id="CD012906-sec-0184"> <h6 class="title">All‐cause mortality</h6> <p>The trial did not report this outcome.</p> </section> <section id="CD012906-sec-0185"> <h6 class="title">Serious adverse events</h6> <p>In the metformin group, 0/56 participants experienced a serious adverse event compared with 0/56 participants in the meglitinide group (very low‐certainty evidence). </p> </section> <section id="CD012906-sec-0186"> <h6 class="title">Health‐related quality of life</h6> <p>The trial did not report this outcome.</p> </section> </section> <section id="CD012906-sec-0187"> <h5 class="title">Secondary outcomes</h5> <section id="CD012906-sec-0188"> <h6 class="title">Severe hypoglycaemia</h6> <p>In the metformin group, 0/56 participants experienced severe hypoglycaemia compared with 0/56 participants in the meglitinide group. </p> </section> <section id="CD012906-sec-0189"> <h6 class="title">Cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, end‐stage renal disease, blindness </h6> <p>The trial did not report these outcomes.</p> </section> </section> <section id="CD012906-sec-0190"> <h5 class="title">Explorative outcomes</h5> <section id="CD012906-sec-0191"> <h6 class="title">Glycaemic control: fasting plasma glucose (FPG)</h6> <p>In the metformin group, the mean FPG was 7.6 mmol/L (SD 0.94) in 49 participants compared with 7.7 mmol/L (SD 1.22) in 53 participants in the meglitinide group. </p> </section> </section> </section> <section id="CD012906-sec-0192"> <h4 class="title">Subgroup analyses</h4> <p>We performed several subgroup analyses. Please see under comparison and outcome of interest. </p> </section> <section id="CD012906-sec-0193"> <h4 class="title">Sensitivity analyses</h4> <p>We performed several sensitivity analyses. Please see under comparison and outcome of interest. </p> </section> <section id="CD012906-sec-0194"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not draw funnel plots since there were no analyses with 10 trials or more for a particular outcome. </p> </section> <section id="CD012906-sec-0195"> <h4 class="title">Ongoing trials</h4> <p>We identified four ongoing RCTs that could potentially provide data of interest for our review. The estimated trial completion dates were: <a href="./references#CD012906-bbs2-0150" title="NCT01001962. Double blind placebo study of JARDIANCE® (Empagliflozin) in prehypertensives type II diabetics. clinicaltrials.gov/ct2/show/NCT01001962 (first posted 27 October 2009). ">NCT01001962</a> (January 2020), <a href="./references#CD012906-bbs2-0151" title="HannonTS , KahnSE , UtzschneiderKM , BuchananTA , NadeauKJ , ZeitlerPS , et al. Review of methods for measuring β-cell function: design considerations from the restoring insulin secretion (RISE) Consortium. Diabetes, Obesity &amp; Metabolism January 2018;20(1):14-24. [DOI: 10.1111/dom.13005]NCT01779362. RISE adult medication study. clinicaltrials.gov/ct2/show/NCT01779362 (first posted 30 January 2013). RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care August 2018;41(8):1696-706. [DOI: 10.2337/dc18-0244]RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test. Diabetes Care August 2018;41(8):1707-16. [DOI: 10.2337/dc18-0243]RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care2014;37(3):780-8. [DOI: 10.2337/dc13-1879]">NCT01779362</a> (August 2019), <a href="./references#CD012906-bbs2-0152" title="CTRI/2014/01/004301. A clinical trial to study the effects of two drugs, vildagliptin and metformin in patients with type 2 diabetes mellitus. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=7817 (first registered 9 January 2014). NCT02853630. A clinical trial to study the effects of two drugs, vildagliptin and metformin in patients with type 2 diabetes mellitus. clinicaltrials.gov/ct2/show/NCT02853630 (first posted 3 August 2016). ">NCT02853630</a> (December 2018) and <a href="./references#CD012906-bbs2-0153" title="NCT03982381. A multicenter, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascular complications. https://clinicaltrials.gov/ct2/show/NCT03982381 (first posted 11 June 2019). ">NCT03982381</a> (September 2024). Three of the trials (<a href="./references#CD012906-bbs2-0150" title="NCT01001962. Double blind placebo study of JARDIANCE® (Empagliflozin) in prehypertensives type II diabetics. clinicaltrials.gov/ct2/show/NCT01001962 (first posted 27 October 2009). ">NCT01001962</a>; <a href="./references#CD012906-bbs2-0151" title="HannonTS , KahnSE , UtzschneiderKM , BuchananTA , NadeauKJ , ZeitlerPS , et al. Review of methods for measuring β-cell function: design considerations from the restoring insulin secretion (RISE) Consortium. Diabetes, Obesity &amp; Metabolism January 2018;20(1):14-24. [DOI: 10.1111/dom.13005]NCT01779362. RISE adult medication study. clinicaltrials.gov/ct2/show/NCT01779362 (first posted 30 January 2013). RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care August 2018;41(8):1696-706. [DOI: 10.2337/dc18-0244]RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test. Diabetes Care August 2018;41(8):1707-16. [DOI: 10.2337/dc18-0243]RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care2014;37(3):780-8. [DOI: 10.2337/dc13-1879]">NCT01779362</a>; <a href="./references#CD012906-bbs2-0152" title="CTRI/2014/01/004301. A clinical trial to study the effects of two drugs, vildagliptin and metformin in patients with type 2 diabetes mellitus. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=7817 (first registered 9 January 2014). NCT02853630. A clinical trial to study the effects of two drugs, vildagliptin and metformin in patients with type 2 diabetes mellitus. clinicaltrials.gov/ct2/show/NCT02853630 (first posted 3 August 2016). ">NCT02853630</a>) are expected to have been completed, but no results have been published. The ongoing trials will include approximately 5824 participants. All of the ongoing trials are investigating one or more outcomes of interest to this review. </p> <p>For further details, see '<a href="./references#CD012906-sec-0243" title="">Characteristics of ongoing studies</a>'. </p> </section> <section id="CD012906-sec-0196"> <h4 class="title">Studies awaiting assessment</h4> <p>We identified 24 RCTs awaiting assessment. All of the trials were expected to have been completed, but no results were published. The trials included approximately 2369 participants. The majority of the studies awaiting assessment investigated one or more outcomes of interest to this review. </p> <p>For further details, see '<a href="./references#CD012906-sec-0242" title="">Characteristics of studies awaiting classification</a>'. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012906-sec-0197" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012906-sec-0197"></div> <section id="CD012906-sec-0198"> <h3 class="title" id="CD012906-sec-0198">Summary of main results</h3> <p>This review investigated metformin monotherapy compared with no intervention, placebo, diet or glucose‐lowering drugs in people with T2DM. We included 18 trials with a total of 10,680 randomised participants. We judged no trials to be at low risk of bias for all 'Risk of bias' domains. The amount of evidence for our primary and secondary outcomes was very limited. Neither metformin nor any of the comparators were clearly favoured in any of the outcomes as specified in the <a href="./full#CD012906-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012906-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012906-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012906-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012906-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012906-tbl-0006">summary of findings Table 6</a>. There were fewer reported cases of severe hypoglycaemia with metformin compared to sulphonylurea. Furthermore, metformin was favoured in the majority of our explorative outcomes. However, many of these results suffered from lack of data and heterogeneity, and were not robust in sensitivity analyses. </p> </section> <section id="CD012906-sec-0199"> <h3 class="title" id="CD012906-sec-0199">Overall completeness and applicability of evidence</h3> <p>We conducted an extensive search for trials in databases and from non‐database sources with no restrictions on language or outcomes reported in trials, and we tried to retrieve additional information on all trials. Additionally, we handsearched reference lists of all trials, which identified two additional publications to be included. The US Food and Drug Administration (FDA) also provided additional information of an included trial (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>). </p> <p>For each trial we contacted one or more authors to obtain supplemental data on outcomes and 'Risk of bias' domains and to specify whether further trials existed. Only one author replied and provided additional data (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>). </p> <p>Diagnostic criteria for T2DM were primarily established using the criteria from the World Health Organization (WHO) and American Diabetes Association (ADA). Eleven trials did not report diagnostic criteria for T2DM. </p> <p>Selection bias may generally be present in randomised controlled trials (RCTs) because the participants could be healthier and more motivated than the population from which they are sampled. However, a Cochrane systematic review demonstrated that participants in RCTs had similar clinical outcomes compared with patients who did not participate (<a href="./references#CD012906-bbs2-0216" title="VistGE , BryantD , SomervilleL , BirminghemT , OxmanAD . Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: MR000009. [DOI: 10.1002/14651858.MR000009.pub4]">Vist 2008</a>). </p> <p>We were not able to include patient‐important data from the longest follow‐up period in the UKPDS trial (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). The importance of the UKDPS trial is based on the length of the intervention: about 10 years. According to the design description, the researchers planned to compare the subgroup of overweight and obese participants randomly assigned to receive insulin or sulphonylureas or metformin monotherapy. However, to our knowledge, these data have not been reported separately. Instead, the participants assigned to sulphonylureas or insulin were grouped together, which precludes direct comparison of sulphonylureas with metformin and insulin with metformin. However, in some of the co‐publications, some information on outcomes with relevance (e.g. severe hypoglycaemia, glycaemic control) for this review could be retrieved after one to three years of follow‐up. The largest trial reporting patient‐important outcomes for sulphonylurea monotherapy compared with metformin was the A Diabetes Outcome Progression Trial (ADOPT) trial (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>). </p> <p>We could not include mortality or macrovascular complications from the UKPDS trial, therefore our review consists exclusively of trials that did not predefine mortality or cardiovascular complications as their primary outcome and instead reported them as adverse events (deaths). This might have led to bias arising from trial design features, such as lack of adjudication of events. </p> </section> <section id="CD012906-sec-0200"> <h3 class="title" id="CD012906-sec-0200">Quality of the evidence</h3> <p>We judged all trials to be at unclear or high risk of bias for at least one of the 'Risk of bias' domains. The description or procedure of randomisation was inadequate in 11 trials (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>; <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a>; <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>; <a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a>; <a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>). </p> <p>All but two trials (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) inadequately reported one or more outcomes of interest for our review, and we consequently judged them to be at high risk of selective outcome reporting bias. </p> <p>All included trials reported at least one of our outcomes.</p> <p>For all outcomes specified in the <a href="./full#CD012906-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012906-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012906-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012906-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012906-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012906-tbl-0006">summary of findings Table 6</a>, we judged the evidence to be of very low certainty mainly due to risk of bias and serious imprecision. </p> <p>Only one trial was solely funded by an university (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>). The remaining trials did not report funding source or received funding from the pharmaceutical industry. Trials investigating free drugs or devices sponsored by a pharmaceutical company have been shown to produce more favourable results and conclusions than trials receiving funding from other sources (<a href="./references#CD012906-bbs2-0196" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] [PMID: 28207928]">Lundh 2017</a>). </p> </section> <section id="CD012906-sec-0201"> <h3 class="title" id="CD012906-sec-0201">Potential biases in the review process</h3> <p>Due to inclusion of few trials for most of the comparisons, we were unable to perform meta‐analyses on all outcomes. For some outcomes, very limited or even no data were available (health‐related quality of life, end‐stage renal disease, blindness, lactic acidosis, amputation of lower extremity and socioeconomic effects). For the same reason, we were unable to draw funnel plots to assess small‐study bias; sensitivity and subgroup analysis could only be performed on a subset of outcomes; and we were not able to explore reasons for heterogeneity in details. </p> <p>We contacted one or more authors of all the included trials. However, only one author provided additional data which did not substantially change the certainty of the evidence for this trial. </p> <p>We designed our inclusion criteria to include trials with a minimum duration of 52 weeks because we were interested in long‐term, patient‐important outcomes. Despite the criteria, many of the included trials only reported few of our predefined primary outcomes. </p> <p>Two review authors independently performed selection of trials, data extraction and 'Risk of bias' assessments. However, review authors were not blinded as to which trial they were working with, which could potentially have biased the review process. </p> </section> <section id="CD012906-sec-0202"> <h3 class="title" id="CD012906-sec-0202">Agreements and disagreements with other studies or reviews</h3> <p>We checked 16 systematic reviews of RCTs that had metformin monotherapy as an intervention of interest to assess concordance between other results and those of our review (<a href="./references#CD012906-bbs2-0027" title="BillingtonEO , GreyA , Boll, MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia2015;58(10):2238-46. ">Billington 2015</a>; <a href="./references#CD012906-bbs2-0029" title="BoussageonR , SupperI , Bejan-AngoulvantT , KellouN , CucheratM , Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine2012;9(4):e1001204. ">Boussageon 2012</a>; <a href="./references#CD012906-bbs2-0032" title="BuhseS , MuhlhauserI , LenzM . The 'old' anti-diabetic agents: a systematic inventory. Endocrine Development2016;31:28-42. ">Buhse 2016</a>; <a href="./references#CD012906-bbs2-0033" title="CaiX , YangW , GaoX , ZhouL , HanX , JiL . Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: a meta-analysis. PLOS One2016;11(12):e0166625. ">Cai 2016</a>; <a href="./references#CD012906-bbs2-0037" title="ChengJW , BadreldinHA , PatelDK , BhattSH . Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Current Medical Research and Opinion2017;33(6):985-92. ">Cheng 2017</a>; <a href="./references#CD012906-bbs2-0062" title="GuS , ShiJ , TangZ , SawhneyM , HuH , ShiL , et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLOS One2015;10(5):e0126704. GuS , XuX , ShiL , SawhneyM , HuH , DongH . Cost minimization analysis of clinical option scenarios for metformin and acarbose in treatment of type 2 diabetes: based on direct and indirect treatment comparison results. Value in Health2014;17(7):A745. ">Gu 2014</a>; <a href="./references#CD012906-bbs2-0065" title="HirstJA , FarmerAJ , RobertsNW , PluddemannA , HarrisonS , AliR , et al. A systematic review of the effect of metformin treatment on glycaemic control in diabetes patients. Diabetic Medicine2012;28:202. ">Hirst 2012</a>; <a href="./references#CD012906-bbs2-0070" title="IdaS , MurataK , KanekoR . Effects of metformin treatment on blood leptin and ghrelin levels in patients with type 2 diabetes mellitus. Journal of Diabetes2017;9(5):526-35. ">Ida 2017</a>; <a href="./references#CD012906-bbs2-0080" title="LiuQ , LiS , QuanH , LiJ . Vitamin B12 status in metformin treated patients: systematic review. PLOS One2014;9(6):e100379. ">Liu 2014</a>; <a href="./references#CD012906-bbs2-0087" title="MonamiM , DicembriniI , KundisovaL , ZannoniS , NreuB , MannucciE . A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2014;16(9):833-40. ">Monami 2014</a>; <a href="./references#CD012906-bbs2-0106" title="PalmerSC , MavridisD , NicolucciA , JohnsonDW , TonelliM , CraigJC , et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA2016;316(3):313-24. ">Palmer 2016</a>; <a href="./references#CD012906-bbs2-0110" title="RokkasT , PortincasaP . Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. European Journal of Internal Medicine2016;33(-):60-6. ">Rokkas 2016</a>; <a href="./references#CD012906-bbs2-0204" title="SaenzA , Fernandez-EstebanI , MataixA , AusejoM , RoqueM , MoherD . Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002966. [DOI: 10.1002/14651858.CD002966.pub3]">Saenz 2005</a>; <a href="./references#CD012906-bbs2-0113" title="SalpeterS , GreyberE , PasternakG , SalpeterE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2003, Issue 2. Art. No: CD002967. [DOI: 10.1002/14651858.CD002967.pub3]">Salpeter 2003</a>; <a href="./references#CD012906-bbs2-0123" title="ZhangL , ZhangM , ZhangY , TongN . Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Scientific Reports2016;6:18904. ">Zhang 2016</a>; <a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>). </p> <p>Two of the systematic reviews performed network meta‐analyses when estimating effect sizes and reported mixed‐effect results comprising direct and indirect evidence (<a href="./references#CD012906-bbs2-0106" title="PalmerSC , MavridisD , NicolucciA , JohnsonDW , TonelliM , CraigJC , et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA2016;316(3):313-24. ">Palmer 2016</a>; <a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>). The population of interest was exclusively participants with T2DM in all but two systematic reviews (<a href="./references#CD012906-bbs2-0027" title="BillingtonEO , GreyA , Boll, MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia2015;58(10):2238-46. ">Billington 2015</a>; <a href="./references#CD012906-bbs2-0080" title="LiuQ , LiS , QuanH , LiJ . Vitamin B12 status in metformin treated patients: systematic review. PLOS One2014;9(6):e100379. ">Liu 2014</a>), in which participants were healthy or had polycystic ovary syndrome, respectively. Metformin monotherapy was primarily compared with placebo, diet, no treatment or glucose‐lowering drugs. The most common outcomes of the systematic reviews were HbA1c, cardiovascular mortality, myocardial infarction, stroke, all‐cause mortality and adverse events. Two systematic reviews did not share any outcomes with our review (<a href="./references#CD012906-bbs2-0027" title="BillingtonEO , GreyA , Boll, MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia2015;58(10):2238-46. ">Billington 2015</a>; <a href="./references#CD012906-bbs2-0070" title="IdaS , MurataK , KanekoR . Effects of metformin treatment on blood leptin and ghrelin levels in patients with type 2 diabetes mellitus. Journal of Diabetes2017;9(5):526-35. ">Ida 2017</a>). Five systematic reviews did not perform any meta‐analyses of metformin monotherapy versus comparator for our outcomes, primarily due to lack of data (<a href="./references#CD012906-bbs2-0032" title="BuhseS , MuhlhauserI , LenzM . The 'old' anti-diabetic agents: a systematic inventory. Endocrine Development2016;31:28-42. ">Buhse 2016</a>; <a href="./references#CD012906-bbs2-0037" title="ChengJW , BadreldinHA , PatelDK , BhattSH . Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Current Medical Research and Opinion2017;33(6):985-92. ">Cheng 2017</a>; <a href="./references#CD012906-bbs2-0080" title="LiuQ , LiS , QuanH , LiJ . Vitamin B12 status in metformin treated patients: systematic review. PLOS One2014;9(6):e100379. ">Liu 2014</a>; <a href="./references#CD012906-bbs2-0110" title="RokkasT , PortincasaP . Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. European Journal of Internal Medicine2016;33(-):60-6. ">Rokkas 2016</a>; <a href="./references#CD012906-bbs2-0123" title="ZhangL , ZhangM , ZhangY , TongN . Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Scientific Reports2016;6:18904. ">Zhang 2016</a>). For one systematic review (<a href="./references#CD012906-bbs2-0065" title="HirstJA , FarmerAJ , RobertsNW , PluddemannA , HarrisonS , AliR , et al. A systematic review of the effect of metformin treatment on glycaemic control in diabetes patients. Diabetic Medicine2012;28:202. ">Hirst 2012</a>), only the citation was identified and could not be investigated any further. </p> <p>Four systematic reviews showed no substantial difference between metformin and any glucose‐lowering drug for all‐cause mortality (<a href="./references#CD012906-bbs2-0029" title="BoussageonR , SupperI , Bejan-AngoulvantT , KellouN , CucheratM , Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine2012;9(4):e1001204. ">Boussageon 2012</a>; <a href="./references#CD012906-bbs2-0106" title="PalmerSC , MavridisD , NicolucciA , JohnsonDW , TonelliM , CraigJC , et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA2016;316(3):313-24. ">Palmer 2016</a>), cardiovascular mortality (<a href="./references#CD012906-bbs2-0029" title="BoussageonR , SupperI , Bejan-AngoulvantT , KellouN , CucheratM , Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine2012;9(4):e1001204. ">Boussageon 2012</a>; <a href="./references#CD012906-bbs2-0106" title="PalmerSC , MavridisD , NicolucciA , JohnsonDW , TonelliM , CraigJC , et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA2016;316(3):313-24. ">Palmer 2016</a>), myocardial infarction, heart failure, peripheral revascularisation, amputation (<a href="./references#CD012906-bbs2-0029" title="BoussageonR , SupperI , Bejan-AngoulvantT , KellouN , CucheratM , Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine2012;9(4):e1001204. ">Boussageon 2012</a>), lactic acidosis (<a href="./references#CD012906-bbs2-0113" title="SalpeterS , GreyberE , PasternakG , SalpeterE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2003, Issue 2. Art. No: CD002967. [DOI: 10.1002/14651858.CD002967.pub3]">Salpeter 2003</a>) or hypoglycaemia (<a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>). One systematic review showed no difference between metformin and sulphonylurea for severe hypoglycaemia (<a href="./references#CD012906-bbs2-0087" title="MonamiM , DicembriniI , KundisovaL , ZannoniS , NreuB , MannucciE . A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2014;16(9):833-40. ">Monami 2014</a>). For HbA1c, metformin was favoured versus placebo in three systematic reviews (<a href="./references#CD012906-bbs2-0033" title="CaiX , YangW , GaoX , ZhouL , HanX , JiL . Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: a meta-analysis. PLOS One2016;11(12):e0166625. ">Cai 2016</a>; <a href="./references#CD012906-bbs2-0062" title="GuS , ShiJ , TangZ , SawhneyM , HuH , ShiL , et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLOS One2015;10(5):e0126704. GuS , XuX , ShiL , SawhneyM , HuH , DongH . Cost minimization analysis of clinical option scenarios for metformin and acarbose in treatment of type 2 diabetes: based on direct and indirect treatment comparison results. Value in Health2014;17(7):A745. ">Gu 2014</a>; <a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>); versus saxagliptin in one systematic review (<a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>); not favoured versus DPP‐4 inhibitor in one systematic review (<a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>); and no substantial difference between metformin and acarbose in one systematic review (<a href="./references#CD012906-bbs2-0062" title="GuS , ShiJ , TangZ , SawhneyM , HuH , ShiL , et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLOS One2015;10(5):e0126704. GuS , XuX , ShiL , SawhneyM , HuH , DongH . Cost minimization analysis of clinical option scenarios for metformin and acarbose in treatment of type 2 diabetes: based on direct and indirect treatment comparison results. Value in Health2014;17(7):A745. ">Gu 2014</a>). </p> <p>The majority of the identified systematic reviews suffered from methodological flaws including the following: not reporting or sparsely performing 'Risk of bias' assessment of included trials (<a href="./references#CD012906-bbs2-0029" title="BoussageonR , SupperI , Bejan-AngoulvantT , KellouN , CucheratM , Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine2012;9(4):e1001204. ">Boussageon 2012</a>; <a href="./references#CD012906-bbs2-0032" title="BuhseS , MuhlhauserI , LenzM . The 'old' anti-diabetic agents: a systematic inventory. Endocrine Development2016;31:28-42. ">Buhse 2016</a>; <a href="./references#CD012906-bbs2-0037" title="ChengJW , BadreldinHA , PatelDK , BhattSH . Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Current Medical Research and Opinion2017;33(6):985-92. ">Cheng 2017</a>; <a href="./references#CD012906-bbs2-0062" title="GuS , ShiJ , TangZ , SawhneyM , HuH , ShiL , et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLOS One2015;10(5):e0126704. GuS , XuX , ShiL , SawhneyM , HuH , DongH . Cost minimization analysis of clinical option scenarios for metformin and acarbose in treatment of type 2 diabetes: based on direct and indirect treatment comparison results. Value in Health2014;17(7):A745. ">Gu 2014</a>; <a href="./references#CD012906-bbs2-0070" title="IdaS , MurataK , KanekoR . Effects of metformin treatment on blood leptin and ghrelin levels in patients with type 2 diabetes mellitus. Journal of Diabetes2017;9(5):526-35. ">Ida 2017</a>; <a href="./references#CD012906-bbs2-0087" title="MonamiM , DicembriniI , KundisovaL , ZannoniS , NreuB , MannucciE . A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2014;16(9):833-40. ">Monami 2014</a>; <a href="./references#CD012906-bbs2-0110" title="RokkasT , PortincasaP . Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. European Journal of Internal Medicine2016;33(-):60-6. ">Rokkas 2016</a>; <a href="./references#CD012906-bbs2-0123" title="ZhangL , ZhangM , ZhangY , TongN . Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Scientific Reports2016;6:18904. ">Zhang 2016</a>; <a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>); placing language restrictions on trials for inclusion (<a href="./references#CD012906-bbs2-0027" title="BillingtonEO , GreyA , Boll, MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia2015;58(10):2238-46. ">Billington 2015</a>; <a href="./references#CD012906-bbs2-0032" title="BuhseS , MuhlhauserI , LenzM . The 'old' anti-diabetic agents: a systematic inventory. Endocrine Development2016;31:28-42. ">Buhse 2016</a>; <a href="./references#CD012906-bbs2-0033" title="CaiX , YangW , GaoX , ZhouL , HanX , JiL . Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: a meta-analysis. PLOS One2016;11(12):e0166625. ">Cai 2016</a>; <a href="./references#CD012906-bbs2-0037" title="ChengJW , BadreldinHA , PatelDK , BhattSH . Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Current Medical Research and Opinion2017;33(6):985-92. ">Cheng 2017</a>; <a href="./references#CD012906-bbs2-0070" title="IdaS , MurataK , KanekoR . Effects of metformin treatment on blood leptin and ghrelin levels in patients with type 2 diabetes mellitus. Journal of Diabetes2017;9(5):526-35. ">Ida 2017</a>; <a href="./references#CD012906-bbs2-0080" title="LiuQ , LiS , QuanH , LiJ . Vitamin B12 status in metformin treated patients: systematic review. PLOS One2014;9(6):e100379. ">Liu 2014</a>; <a href="./references#CD012906-bbs2-0087" title="MonamiM , DicembriniI , KundisovaL , ZannoniS , NreuB , MannucciE . A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2014;16(9):833-40. ">Monami 2014</a>; <a href="./references#CD012906-bbs2-0110" title="RokkasT , PortincasaP . Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. European Journal of Internal Medicine2016;33(-):60-6. ">Rokkas 2016</a>; <a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>); and not explicitly searching unpublished data (<a href="./references#CD012906-bbs2-0027" title="BillingtonEO , GreyA , Boll, MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia2015;58(10):2238-46. ">Billington 2015</a>; <a href="./references#CD012906-bbs2-0029" title="BoussageonR , SupperI , Bejan-AngoulvantT , KellouN , CucheratM , Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine2012;9(4):e1001204. ">Boussageon 2012</a>; <a href="./references#CD012906-bbs2-0032" title="BuhseS , MuhlhauserI , LenzM . The 'old' anti-diabetic agents: a systematic inventory. Endocrine Development2016;31:28-42. ">Buhse 2016</a>; <a href="./references#CD012906-bbs2-0033" title="CaiX , YangW , GaoX , ZhouL , HanX , JiL . Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: a meta-analysis. PLOS One2016;11(12):e0166625. ">Cai 2016</a>; <a href="./references#CD012906-bbs2-0037" title="ChengJW , BadreldinHA , PatelDK , BhattSH . Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Current Medical Research and Opinion2017;33(6):985-92. ">Cheng 2017</a>; <a href="./references#CD012906-bbs2-0062" title="GuS , ShiJ , TangZ , SawhneyM , HuH , ShiL , et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLOS One2015;10(5):e0126704. GuS , XuX , ShiL , SawhneyM , HuH , DongH . Cost minimization analysis of clinical option scenarios for metformin and acarbose in treatment of type 2 diabetes: based on direct and indirect treatment comparison results. Value in Health2014;17(7):A745. ">Gu 2014</a>; <a href="./references#CD012906-bbs2-0080" title="LiuQ , LiS , QuanH , LiJ . Vitamin B12 status in metformin treated patients: systematic review. PLOS One2014;9(6):e100379. ">Liu 2014</a>; <a href="./references#CD012906-bbs2-0110" title="RokkasT , PortincasaP . Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. European Journal of Internal Medicine2016;33(-):60-6. ">Rokkas 2016</a>; <a href="./references#CD012906-bbs2-0123" title="ZhangL , ZhangM , ZhangY , TongN . Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Scientific Reports2016;6:18904. ">Zhang 2016</a>; <a href="./references#CD012906-bbs2-0125" title="ZintzarasE , MiligkosM , ZiakasP , Balk EM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clinical Therapeutics2014;36(10):1443-53.e9. ">Zintzaras 2014</a>). </p> <p>We exclusively included RCTs of at least 52 weeks because we were primarily interested in long‐term, patient‐important outcomes, and trials less than 52 weeks rarely report these. Despite this difference between our review and the aforementioned systematic reviews, the results for our outcomes are comparable. However, as mentioned above, these results are limited and not conclusive due to very low‐certainty evidence in this review. </p> <p>To the best of our knowledge, our review is currently the only updated systematic review investigating long‐term, patient‐important outcomes of metformin monotherapy in RCTs. </p> <p>The most widely used guidelines recommend metformin as a first‐line antidiabetic drug (<a href="./references#CD012906-bbs2-0157" title="InzucchiSE , BergenstalRM , BuseJB , DiamantM , FerranniniE , NauckM , et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2015;58(3):429-42. [PMID: 25583541]">ADA/EASD 2015</a>). This recommendation may be influenced by the results of the UKPDS trial for the subgroup of overweight and obese participants. However, this trial was of limited size and possibly biased in its reporting of the comparison of sulphonylurea/insulin and metformin because it apparently did not adhere to the predefined statistical analysis plan described in the design article (<a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012906-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram." data-id="CD012906-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012906-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials)" data-id="CD012906-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin vs no intervention, Outcome 1: Glycaemic control: HbA1c" data-id="CD012906-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Metformin vs no intervention, Outcome 1: Glycaemic control: HbA1c</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin vs no intervention, Outcome 2: Glycaemic control: HbA1c (subgroup duration of the intervention)" data-id="CD012906-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Metformin vs no intervention, Outcome 2: Glycaemic control: HbA1c (subgroup duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 1: Severe hypoglycaemia" data-id="CD012906-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 1: Severe hypoglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 2: Severe hypoglycaemia (Subgroup: duration of intervention" data-id="CD012906-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 2: Severe hypoglycaemia (Subgroup: duration of intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 3: Anthropometric measures: BMI" data-id="CD012906-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 3: Anthropometric measures: BMI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 4: Anthropometric measures: body weight" data-id="CD012906-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 4: Anthropometric measures: body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 5: Anthropometric measures: body weight (duration of intervention)" data-id="CD012906-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 5: Anthropometric measures: body weight (duration of intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 6: Glycaemic control: FPG" data-id="CD012906-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 6: Glycaemic control: FPG</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 7: Glycaemic control: FPG (Subgroup: duration of the intervention)" data-id="CD012906-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 7: Glycaemic control: FPG (Subgroup: duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 8: Glycaemic control: HbA1c" data-id="CD012906-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 8: Glycaemic control: HbA1c</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 9: Glycaemic control: HbA1c (Subgroup: duration of the intervention)" data-id="CD012906-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 9: Glycaemic control: HbA1c (Subgroup: duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 10: Intervention failure" data-id="CD012906-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 10: Intervention failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metformin vs sulphonylurea, Outcome 11: Intervention failure (Subgroup: duration of the intervention" data-id="CD012906-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Metformin vs sulphonylurea, Outcome 11: Intervention failure (Subgroup: duration of the intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 1: All‐cause mortality" data-id="CD012906-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 2: All‐cause mortality (Subgroup: duration of the intervention)" data-id="CD012906-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 2: All‐cause mortality (Subgroup: duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 3: Serious adverse events" data-id="CD012906-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 4: Serious adverse event (Subgroup: duration of the intervention)s" data-id="CD012906-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 4: Serious adverse event (Subgroup: duration of the intervention)s </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 5: Cardiovascular mortality" data-id="CD012906-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 5: Cardiovascular mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 6: Cardiovascular mortality Subgroup: duration of the intervention)" data-id="CD012906-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 6: Cardiovascular mortality Subgroup: duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 7: Anthropometric measures: BMI" data-id="CD012906-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 7: Anthropometric measures: BMI </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 8: Anthropometric measures: body weight" data-id="CD012906-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 8: Anthropometric measures: body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 9: Glycaemic control: FPG" data-id="CD012906-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 9: Glycaemic control: FPG</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 10: Glycaemic control: FPG (Subgroup: duration of the intervention)" data-id="CD012906-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 10: Glycaemic control: FPG (Subgroup: duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 11: Glycaemic control: FPG (Subgroup: selection bias)" data-id="CD012906-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 11: Glycaemic control: FPG (Subgroup: selection bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 12: Glycaemic control: HbA1c" data-id="CD012906-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 12: Glycaemic control: HbA1c</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 13: Glycaemic control: HbA1c (Subgroup: duration of the intervention)" data-id="CD012906-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 13: Glycaemic control: HbA1c (Subgroup: duration of the intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 14: Glycaemic control: HbA1c (Subgroup: selection bias)" data-id="CD012906-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 14: Glycaemic control: HbA1c (Subgroup: selection bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 15: Intervention failure" data-id="CD012906-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 15: Intervention failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 16: Intervention failure (Subgroup: duration of the intervention" data-id="CD012906-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 16: Intervention failure (Subgroup: duration of the intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metformin vs thiazolidinedione, Outcome 17: Intervention failure (Subgroup: selection bias)" data-id="CD012906-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Metformin vs thiazolidinedione, Outcome 17: Intervention failure (Subgroup: selection bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 1: All‐cause mortality" data-id="CD012906-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 2: Serious adverse events" data-id="CD012906-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 3: Anthropometric measures: body weight" data-id="CD012906-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 3: Anthropometric measures: body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 4: Glycaemic control: FPG" data-id="CD012906-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 4: Glycaemic control: FPG </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012906-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/urn:x-wiley:14651858:media:CD012906:CD012906-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 5: Glycaemic control: HbA1c" data-id="CD012906-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_t/tCD012906-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Metformin vs dipeptidyl peptidase‐4 inhibitor, Outcome 5: Glycaemic control: HbA1c </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/media/CDSR/CD012906/image_n/nCD012906-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012906-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus insulin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with insulin for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> insulin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>(Short Form‐36 version 2 questionnaire)</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No substantial difference in mental or physical health‐related quality of life between the intervention groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0209">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus insulin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012906-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus sulphonylureas</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with sulphonylureas for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> sulphonylureas (glibenclamide/glyburide, gliclazide, glipizide, glimepiride) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sulphonylureas<br/>(glibenclamide/glyburide, gliclazide, glipizide, glimepiride)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3129 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials: no participant died (<a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a>; <a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>) </p> <p>1 trial: 31/1454 participants (2.1%) in the metformin group died vs 31/1441 participants (2.2%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3081 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no SAE occurred (<a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a>; <a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>) </p> <p>1 trial: 331/1454 participants (22.8%) in the metformin group experienced a SAE compared with 308/1441 participants (21.4%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2940 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no CVM was observed (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>)<br/>1 trial: 4/1455 participants (0.3%) in the metformin group died of cardiovascular reasons vs 8/1447 participants (0.6%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3047 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no NFMI occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>)<br/>1 trial: 21/1454 participants (1.4%) in the metformin group experienced a NFMI vs 15/1441 participants (1.0%) in the sulphonylurea group (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b><br/>Follow‐up: 1‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no NFS occurred (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0210">Appendix 2</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus sulphonylureas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012906-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus thiazolidinediones</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with thiazolidinediones for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> thiazolidinediones (pioglitazone, rosiglitazone) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Thiazolidinediones<br/>(pioglitazone, rosiglitazone)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> (9 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> (0.55 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4402 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no deaths occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) </p> <p>1 trial contributed 65/71 events (91.5%) (<a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b> (184 to 239) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.84 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3208 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no SAE occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (0.21 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3211 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3020 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials: no NFMI occurred (<a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a>; <a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>)<br/>1 trial: 21/1454 participants (1.4%) in the metformin group experienced a NFMI vs 25/1456 participants (1.7%) in the thiazolidinedione group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b> </p> <p>Follow‐up: 1‐4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no NFS occurred (<a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0211">Appendix 3</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus thiazolidinediones</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012906-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus dipeptidyl‐peptidase 4 inhibitors</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with dipeptidyl peptidase‐4 inhibitors for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> dipeptidyl peptidase‐4 inhibitors (saxagliptin, sitagliptin, vildagliptin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dipeptidyl peptidase‐4 inhibitors</b><br/>(saxagliptin, sitagliptin, vildagliptin) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 5/328 (1.5%) participants in the metformin group died vs 2/335 (0.6%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>)<br/>1 trial: 1/364 (0.3%) participants in the metformin group died vs 0/179 in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> <p>1 trial: 4/252 (1.6%) participants in the metformin group died vs 3/519 (0.6%) in the vildagliptin group (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 15/328 (4.5%) participants in the metformin group experienced a SAE vs 16/335 (4.8%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>)<br/>1 trial: 16/364 (4.4%) participants in the metformin group experienced a SAE vs 13/179 (7.2%) participants in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> <p>1 trial: 13/252 (5.2%) participants in the metformin group experienced a SAE vs 35/519 (6.7%) participants in the vildagliptin group (<a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>). </p> <p>1 trial: 3/328 (0.9%) participants in the metformin group died due to cardiovascular disease vs 2/335 (0.6%) participants in the saxagliptin group (<a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 1/364 (0.3%) participants in the metformin group experienced a NFMI vs 0/179 participants in the sitagliptin group (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b> </p> <p>Follow‐up: 1.5‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no NFS occurred (<a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0212">Appendix 4</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus dipeptidyl‐peptidase 4 inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012906-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus glucagon like peptide‐1 analogues</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with glucagon like peptide‐1 analogues for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> glucagon like peptide‐1 analogues (dulaglutide) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Glucagon like peptide‐1 analogues<br/>(dulaglutide)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" class="headercell" colspan="6" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no deaths occurred (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 16/268 (6.0%) participants in the metformin group experienced a SAE vs 35/539 (6.5%) participants in the dulaglutide group (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (CVM)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no deaths due to cardiovascular reasons occurred (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (NFMI)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 0/268 participants in the metformin group experienced a NFMI vs 1/539 (0.2%) participants in the dulaglutide group (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (NFS)</b> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: 0/268 participants in the metformin group experienced a NFS vs 1/539 (0.2%) participants in the dulaglutide group (<a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>NFMI</b> : non‐fatal myocardial infarction; <b>NFS</b> : non‐fatal stroke; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0213">Appendix 5</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus glucagon like peptide‐1 analogues</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012906-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus meglitinides</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Metformin monotherapy compared with another glucose‐lowering drug for adults with type 2 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin monotherapy </p> <p><b>Comparison:</b> meglitinide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metiglinide<br/>(repaglinide)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metformin monotherapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial: no SAE occurred (<a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of risk of bias and serious imprecision ‐ see <a href="./appendices#CD012906-sec-0214">Appendix 6</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus meglitinides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012906-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID<br/>(trial design)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial<br/>(N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial<br/>(%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0001" title="BilezikianJP , JosseRG , EastellR , LewieckiEM , MillerCG , WooddellM , et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2013;98(4):1519-28. FitzpatrickLA , BilezikianJP , WooddellM , PaulG , KolatkarNS , Nino AJ , et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. Journal of Drug Assessment2012;1(0):11-9. MillerCG , BogadoCC , NinoAJ , NortcuttR , YuHJ , LewieckiEM , et al. Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial With rosiglitazone: a potential new study endpoint. Journal of Clinical Densitometry: Assessment &amp; Management of Musculoskeletal Health2016;19(4):485-91. NCT00679939. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. clinicaltrials.gov/ct2/show/NCT00679939 (first posted 19 May 2008). RubinMR , ManavalanJS , AgarwalS , McMahonDJ , NinoA , FitzpatrickLA , et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2014;99(10):1933-42. ">Bilezikian 2013</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Sample size calculation was based on a 30% dropout rate and a SD of 4% for percentage change from baseline in femoral neck, ensuring that the 95% confidence interval will be the mean +‐ 0.9% for each treatment group" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>226</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>225</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>162</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>71.7</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0006" title="EremC , Ozbas HM , NuhogluI , DegerO , CivanN , Ersoz HO . Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and Clinical Endocrinology &amp; Diabetes2014;122(5):295-302. ">Erem 2014</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: gliclazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>57</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>57</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0005" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental2009;58(8):1059-66. ">Derosa 2009</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Considering as clinically significant a difference of at least 10% compared with the baseline and an α error of.05, the actual sample size is adequate to obtain a power higher than 0.80 for all variables related to glucose metabolism (HbA1c, FPG, PPG, FPI, PPI, GIR, and TGR)." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>15 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>136</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>120</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>88.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0007" title="HomePD , KahnSE , JonesNP , NoronhaD , Beck-NielsenH , VibertiG , et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838-45. KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine2006;355(23):2427-43. KrallRL . Cardiovascular safety of rosiglitazone. Lancet2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]LachinJM , VibertiG , ZinmanB , HaffnerSM , AftringRP , PaulG , et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology2011;6(5):1032-40. NCT00279045. Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. clinicaltrials.gov/ct2/show/NCT00279045 (first posted 19 January 2006). VibertiG , KahnSE , GreeneDA , HermanWH , ZinmanB , HolmanRR , et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care2002;25(10):1737-43. VibertiG , LachinJ , HolmanR , ZinmanB , HaffnerS , KravitzB , et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabetic Medicine2006;23(12):1289-94. ">Kahn 2006</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"We originally calculated that we would need to enroll 3600 patients to provide the study with a power of 90% to detect a 30% reduction in the risk of treatment failure for rosiglitazone, as compared with metformin and glyburide, at a significance level of P=0.05 (two‐sided, adjusted for two comparisons), assuming an event rate of 0.072 per year for metformin or glyburide and a rate of loss to follow‐up of 0.064 per year in each group. The protocol was amended in March 2002 to increase the number of patients to 4182 and in February 2004, to extend the follow‐up period beyond 4 years, in order to compensate for an overall rate of withdrawal that was greater than anticipated and an overall rate of primary outcome events that was lower than anticipated. The revised power estimate was 83%, assuming a rate of loss to follow‐up of 0.128 per year and a hazard rate for treatment failure of 0.035 per year." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Median of 4 years (maximum 6.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: rosiglitazone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.8</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4360</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4351</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2627</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A planned sample size of 660 patients (in 2 : 1 allocation ratio to vildagliptin: metformin) was calculated assuming a 20% drop‐out rate, with 90% power and a one‐sided significance level of 0.025 to detect non‐inferiority of vildagliptin compared with metformin in reducing HbA1c after 52 weeks, with a noninferiority margin of 0.3% and an expected difference between the two treatment groups of 0.0%. Based on health authority feedback, the test of non‐inferiority was amended during the course of the study to utilize a non‐inferiority margin of 0.4%, which increased the statistical power to 99%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254 (158)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 (158)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 (142)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.2 (55.9)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>526 (305)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511 (304)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378 (260)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.9 (49.4)<sup>b</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>780 (463)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>760 (462)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>569 (402)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>73.5 (52.7)<sup>b</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0016" title="BoustaniMA , PittmanI , YuM , ThieuVT , VarnadoOJ , JunejaR . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and &lt; 65 years. Diabetes, Obesity &amp; Metabolism2016;18(8):820-8. NCT01126580. A study in participants with type 2 diabetes mellitus (AWARD-3). clinicaltrials.gov/ct2/show/NCT01126580 (first posted 19 May 2010). ReaneyM , YuM , LakshmannM , PechtnerV , BruntKV . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes, Obesity &amp; Metabolism2015;17(9):896-903. UmpierrezG , PovedanoST , ManghiFP , ShurzinskeL , PechtnerV . Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014;37(8):2168-76. YuM , BruntKV , VarnadoOJ , BoyeKS . Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes, Obesity &amp; Metabolism2016;18(4):419-24. ">Umpierrez 2014</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The study was designed with 90% power to detect noninferiority of dulaglutide 1.5 mg versus metformin on HbA1c change from baseline at the 26‐week primary end point with a margin of 0.4%, a SD of 1.3%, and a one‐sided a of 0.025, assuming no true difference between treatments. This corresponds to 251 patients per arm, with an assumed dropout rate of 11%. If noninferiority was met, superiority was assessed using a tree‐gatekeeping approach in which the type I error rate across all treatment comparisons for change from baseline in HbA1c at 26 weeks was strongly controlled at 0.025 (onesided). P values were adjusted so that each can be compared with 0.025 to assess significance while accounting for multiplicity adjustments. The analyses of efficacy and safety were based on the intent‐to‐treat population consisting of all randomized patients who received at least one dose of study treatment." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: dulaglutide (1.5 mg/week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: dulaglutide (0.75 mg/week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.7</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>807</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>807</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>651</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>80.7</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0008" title="KiyiciS , ErsoyC , KaderliA , FazliogluM , BudakF , DuranC , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice2009;86(1):44-50. ">Kiyici 2009</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0010" title="JadzinskyM , PfütznerA , Paz-PachecoE , XuZ , AllenE , ChenR , for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity &amp; Metabolism2009;11(6):611-22. NCT00327015. A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. clinicaltrials.gov/ct2/show/NCT00327015 (first posted 17 May 2006). PfütznerA , Paz-PachecoE , AllenE , FrederichR , ChenR , for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity &amp; Metabolism2011;13(6):567-76. ">Pfützner 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"...each comparison was performed at the 0.027 alpha level from Dunnett’s adjustment so that the overall (family‐wise) type I error rate was controlled at the 0.05 significance level." </p> <p>"Based on the primary end‐point, the sample size afforded at least 90% power for both the combination comparisons and the individual components based on the min test by Laska and Meisner for normal case." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>76 weeks<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>663</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>663</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>428</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>64.6</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A noninferiority design was used in this study. Sample size was based on the study objective to disprove the null hypothesis that pioglitazone was inferior to metformin in terms of reduction in HbA1c. Based on a 5% significance level and a statistical power of 90%, a sample size of 450 patients in each treatment group was required." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>— (597<sup>e</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>— (597<sup>e</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1199</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1194</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1000</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>83.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0018" title="YamanouchiT , SakaiT , IgarashiK , IchiyanagiK , WatanabeH , KawasakiT . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine2005;22(8):980-5. ">Yamanouchi 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"Our pretrial calculation showed that a two‐sided comparison of the pioglitazone vs. the diet‐alone group in Japanese patients required at least 30 patients per group to detect a difference in mean HbA1c of at least 1% with 5% significance and 95% power" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: glimepiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>114</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>106</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>106</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>93.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0017" title="GoldsteinBJ , FeinglosMN , LuncefordJK , JohnsonJ , Williams-HermanDE , for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30(8):1979-87. NCT00103857. MK0431 (sitagliptin) and metformin co-administration factorial study in patients with type 2 diabetes mellitus (0431-036). clinicaltrials.gov/ct2/show/NCT00103857 (first posted 16 February 2005). Williams-HermanD , JohnsonJ , TengR , GolmG , KaufmanKD , GolsteinBJ , et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2010;12(5):442-51. Williams-HermanD , JohnsonJ , TengR , LuoE , DaviesMJ , KaufmanKD , et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion2009;25(3):569-83. ">Williams‐Herman 2010</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin (1000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 weeks<sup>f</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: metformin (2000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>543</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—<sup>g</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>240</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>44.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glimepiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>204</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>204</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0002" title="CampbellIW , MenzisDG , ChalmersJ , McBainAM , BrownIRF . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete &amp; Metabolisme1994;20(4):394-400. FDA report. FDA approved drug products [Metformin]. www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf (last accessed 20 September 2019). ">Campbell 1994</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glipizide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>48</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0004" title="DerosaG , FranzettiI , GadaletaG , CiccarelliL , FogariR . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Diabetes, Nutrition &amp; Metabolism2004;17(3):143-50. ">Derosa 2004</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The power of the study was calculated with a Fisher's exact test, with a 0.050 two‐sided significance alpha level and a 90% power; to detect the difference between a glimepiride group proportion of 0.500 and a metformin group proportion of 0.750 the sample size in each group would be 85." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>60 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glimepiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>164</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>148</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>148</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"Table 6 gives the likelihood of detecting a 20 % or 25 % reduction of endpoints by improved plasma glucose and blood pressure control. This reduction has been accepted as being a clinically significant gain, particularly as benefits from treatment are likely to be even greater over a longer period of therapy since complications develop over many years. Power calculations assumed 8 % loss to follow‐up and a 4% per annum increased number of events as the cohort ages" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10.7 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1028</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1028</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0014" title="TeupeB , BergisK . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete &amp; Metabolisme1991;17(1 Pt 2):213-7. ">Teupe 1991</a><sup>h</sup> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>54</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>54</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>54.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012906-bbs2-0003" title="DerosaG , MugelliniA , CiccarelliL , CrescenziG , FogariR . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice2003;60(3):161-9. ">Derosa 2003</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>14 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: repaglinide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>112</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.1</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Grand total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All interventions</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4041<sup>i</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2463<sup>j</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All c</b> omparator<b>s</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6639<sup>i</sup> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>3732<sup>j</sup> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All interventions and c</b> omparator<b>s</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10,680<sup>i</sup> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6195<sup>j</sup> </b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>—: denotes not reported<br/><sup>a</sup>After 52 weeks of metformin versus rosiglitazone all participants received open‐label metformin for an additional 24 weeks, which was not of interest to this review<br/><sup>b</sup>Participants also completing the 52‐week extension<br/><sup>c</sup>The trial consisted of a 52‐week intervention followed by a 52‐week extension period in which participants continued their allocated intervention<br/><sup>d</sup>The trial consisted of a 24‐week intervention followed by a 52‐week extension period in which participants continued their allocated intervention<br/><sup>e</sup>At least 597 participants were randomised to either arm. It is unclear which arm the remaining 5 participants were randomised to<br/><sup>f</sup>The trial consisted of a 24‐week intervention followed by a 30‐week extension period followed by an additional 52‐week extension period in which participants continued their allocated intervention<br/><sup>g</sup>Variation in number of participants analysed depending on outcome measure<br/><sup>h</sup>Results are after 2 years of intervention and follow‐up<br/><sup>i</sup>For <a href="./references#CD012906-bbs2-0013" title="GökeB , HershonK , KerrD , PascualAC , SchweizerA , FoleyJ , et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research2008;40(12):892-5. NCT00099866. Efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00099866 (first posted 22 December 2004). NCT00138567. Extension to a study on the efficacy and safety of vildagliptin compared to metformin in drug naive patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00138567 (first posted 30 August 2005). PratleyRE , RosenstockJ , Pi-Sunyer FX , BanerjuMA , SchweizerA , CouturierA , et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care2007;30(12):3017-22. PratleyRE , SchweizerA , RosenstockJ , FoleyJE , Banerji MA , Pi-SunyerFX , et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity &amp; Metabolism2008;10(10):931-8. SchweizerA , CouterierA , FoleyJE , DejagerS . Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine2007;24(9):955-61. ">Schweizer 2007</a> numbers outside parentheses were used, for <a href="./references#CD012906-bbs2-0012" title="SchernthanerG , MatthewsDR , CharbonnelB , HanefeldM , BrunettiP , on behalf of the Quarter Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism2004;89(12):6068-76. ">Schernthaner 2004</a> numbers in parentheses were used<br/><sup>j</sup>For <a href="./references#CD012906-bbs2-0011" title="RahmanIU , MalikSA , BashirM , KhanRU , IdreesM . Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British Journal of Diabetes &amp; Vascular Disease2011;11:137-40. ">Rahman 2011</a>, <a href="./references#CD012906-bbs2-0015" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359(15):1577-89. [PMID: 18784090]TurnerRC , HolmanRR , MathewsDR , OakesSF , BassettPA , StrattonIM , et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877-90. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):854-65. [PMID: 9742977]UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical Research Ed.)1995;310(6972):83-8. [PMID: 7833731]">UKPDS 34 1998</a> and <a href="./references#CD012906-bbs2-0009" title="OnuchinSG , ElsukovaOS , Solovyev OV , OnuchinaEL . Capablities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus [Russian]. Terapevticheskii Arkhiv2010;82(8):34-41. ">Onuchin 2010</a> no numbers were available and thus not included in calculation </p> <p><b>C</b> : comparator; <b>I</b> : intervention; <b>GIR</b> : glucose infusion rate; <b>ITT</b> : intention‐to‐treat; <b>RCT</b> : randomised controlled trial; <b>SD</b> : standard deviation; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>FPG</b> : fasting plasma glucose; <b>FPI</b> : fasting plasma insulin; <b>PPG</b> : post prandial glucose; <b>PPI</b>: post prandial insulin. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/full#CD012906-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012906-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin vs no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Glycaemic control: HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.45, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Glycaemic control: HbA1c (subgroup duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.45, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.70, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.56, 0.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin vs no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012906-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin vs sulphonylurea</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Second‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Third‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Severe hypoglycaemia (Subgroup: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Anthropometric measures: BMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Second‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐2.53, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Third‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.26, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Anthropometric measures: body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.86 [‐5.18, ‐2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Second‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.54 [‐5.20, ‐3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Third‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.06 [‐3.49, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Anthropometric measures: body weight (duration of intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.86 [‐5.18, ‐2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.50 [‐5.31, ‐3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.49 [‐5.81, ‐1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Glycaemic control: FPG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.54, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Second‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.01, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Third‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.32, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Glycaemic control: FPG (Subgroup: duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.54, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.83, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.52, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Glycaemic control: HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.45, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Second‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.85, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Third‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.15, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Glycaemic control: HbA1c (Subgroup: duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.45, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.35, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.60, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Intervention failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.57, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Second‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.56, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Third‐generation sulphonylurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.12, 67.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Intervention failure (Subgroup: duration of the intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.57, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.56, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.12, 67.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin vs sulphonylurea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012906-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin vs thiazolidinedione</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.55, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.56, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 All‐cause mortality (Subgroup: duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.55, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.56, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.12, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Serious adverse event (Subgroup: duration of the intervention)s <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.24, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.21, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.21, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Cardiovascular mortality Subgroup: duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.22, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Anthropometric measures: BMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐2.34, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐2.82, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐4.78, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Anthropometric measures: body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐15.21, 12.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.60 [‐2.31, 15.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.70 [‐8.44, ‐6.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Glycaemic control: FPG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.10, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.61, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Glycaemic control: FPG (Subgroup: duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.57, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.32, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Glycaemic control: FPG (Subgroup: selection bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Low risk of selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐0.58, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Unclear or high risk of selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.38, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Glycaemic control: HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.18, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.19, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.19, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Glycaemic control: HbA1c (Subgroup: duration of the intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.18, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.15, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.17, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Glycaemic control: HbA1c (Subgroup: selection bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.18, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 Low risk of selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.22, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.2 Unclear or high risk of selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.29, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Intervention failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.18, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Intervention failure (Subgroup: duration of the intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.18, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 Long duration (2 years or more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.2 Short duration (less than 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Intervention failure (Subgroup: selection bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.18, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.1 Low risk of selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.2 Unclear or high risk of selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin vs thiazolidinedione</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012906-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metformin vs dipeptidyl peptidase‐4 inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Anthropometric measures: body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Glycaemic control: FPG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Glycaemic control: HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Saxagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Vildagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 Sitagliptin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metformin vs dipeptidyl peptidase‐4 inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012906.pub2/references#CD012906-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012906.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012906-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012906-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012906-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012906-note-0021">Français</a> </li> <li class="section-language"> <a class="" href="id#CD012906-note-0019">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD012906-note-0016">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012906-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012906-note-0022">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012906-note-0015">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012906-note-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012906-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012906-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012906\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012906\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012906\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012906\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012906\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012906.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012906.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012906.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012906.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012906.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720264996"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012906.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720265000"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012906.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfcea39f99377',t:'MTc0MDcyMDI2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 